Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesImmunology/RheumatologyBlue Cross Blue Shield SC prior auth coverage | Op…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    Drug-specific medical necessity and prior authorization criteria (partial list)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This section summarizes outpatient specialty drug coverage criteria, required documentation, prescriber and age restrictions, prerequisite therapy and reauthorization rules for BCBS‑SC members.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyDrug-specific medical necessity and prior authorization criteria (partial list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required test results or biomarker documentation, prescriber specialty, and trial/failure history as specified for the drug and indication.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~40+products listed in this excerpt
    12 monthstypical coverage duration
    6 monthsinitial coverage durations (some)
    requires specialty consultrequires specialist prescriber

    Drug-specific Coverage Criteria (Initial and Renewal)

    Adalimumab-class biologics — Initial therapy criteria (representative)

    Covered when ALL of the following are met

    Diagnosis of the specified condition (eg, moderately to severely active RA, PJIA, PsA, PsO, AS, CD, UC, HS, uveitis) as documented by provider

    See indication-specific bullet criteria in policy

    Prior therapy: Minimum trial and failure, contraindication, or intolerance (TF/C/I) to specified conventional therapies at maximally tolerated doses (eg, methotrexate, leflunomide, sulfasalazine for RA; topical therapies for psoriasis)

    Duration varies by indication (eg, 3 months for RA; 6 weeks for PJIA; 30 days for topical psoriasis)

    Prescriber: Prescribed by or in consultation with the specified specialist for the indication (eg, rheumatologist for RA, dermatologist for PsO)

    Ulcerative Colitis — Initial and reauthorization

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyDrug-specific medical necessity and prior authorization criteria (partial list)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization with diagnosis, required test results or biomarker documentation, prescriber specialty, and trial/failure history as specified for the drug and indication.
    SourceLink
    On This Page
    Drug-specific Coverage Criteria (Initial and Renewal)Prior Authorization, Documentation & Step Therapy RequirementsReferenced Products and Coding NotesClinical Definitions and ThresholdsPolicy Excerpt Context and Scope

    Covered when ALL of the following are met

    Diagnosis of moderately to severely active ulcerative colitis with objective features (eg, >6 stools/day, frequent blood, urgency, ulcers, abnormal labs)
    Prior treatments: Dependent on, or refractory to, corticosteroids; documentation of trials/failure of conventional therapies (aminosalicylates, immunomodulators) as specified

    Initial UC coverage duration: 12 weeks; reauth: 12 months

    Alpha-1 antitrypsin augmentation (Prolastin-C)

    Covered when ALL of the following are met

    Diagnosis of congenital alpha-1 antitrypsin (AAT) deficiency with emphysema

    Continued conventional emphysema treatment required

    Genotype or level: Either: homozygous severe genotypes (eg, PiZZ, PiZ(null), Pi(null)(null)) OR other pathogenic genotypes with pre-treatment serum AAT < 11 µM/L (or equivalent mg/dL)<11 µM/L

    Corresponding mg/dL values accepted

    CGRP inhibitors for migraine (Aimovig)

    Covered when ALL of the following are met

    Migraine frequency: Episodic migraine: ≥4 migraine days/month OR Chronic migraine: ≥8 migraine days/month

    Medication overuse must be addressed; not to be combined with another CGRP inhibitor

    Prior therapy and monitoring: Medication overuse considered and discontinued when present; documentation of prior acute therapy failures or intolerance as required; reauthorization requires decreased use of acute meds and clinical response

    Initial: 6 months; reauth: 12 months

    Pulmonary arterial hypertension (sildenafil/tadalafil/riociguat/others)

    Covered when ALL of the following are met

    Diagnosis confirmation: Diagnosis of symptomatic pulmonary arterial hypertension (PAH) confirmed by right heart catheterization OR patient currently receiving therapy for PAH

    Prescribed by or in consultation with a pulmonologist or cardiologist; initial: 6 months; reauth: 12 months

    Selected product criteria (examples)

    Each product entry lists required conditions for approval; examples extracted below represent the exact AND/OR requirements as stated for particular drugs in this segment.

    Arformoterol (COPD): Diagnosis of COPD (including chronic bronchitis and emphysema) AND use for maintenance treatment of bronchoconstriction

    Coverage duration 12 months; subject to Part B vs. Part D review

    Antimicrobial and tumor-targeted therapy criteria

    Arikayce (MAC lung disease): Diagnosis of Mycobacterium avium complex (MAC) lung disease AND failure to achieve at least two negative sputum cultures after a minimum of 6 consecutive months of multidrug background regimen

    Prescribed by or in consultation with infectious disease specialist or pulmonologist; coverage 12 months

    Augtyro (ROS1 / NTRK-targeted): Diagnosis of NSCLC with ROS1 rearrangement OR solid tumor with NTRK fusion AND disease locally advanced/metastatic/unresectable AND disease progressed after prior therapy or no satisfactory alternatives

    Prescribed by appropriate specialist; coverage 12 months; prerequisite Part D drug as specified

    Benlysta criteria

    Benlysta (SLE, lupus nephritis): Active systemic lupus erythematosus (SLE) with autoantibody positivity (ANA ≥1:80 or anti-dsDNA ≥30 IU/mL) AND currently receiving at least one standard-of-care therapy; for lupus nephritis, receiving standard-of-care (eg, corticosteroids plus mycophenolate)

    Prescribed by or in consultation with rheumatologist (SLE) or nephrologist; age ≥5 years for IV/SC formulations; coverage 6 months; reauth requires positive clinical response

    Bronchitol criteria

    Bronchitol (Cystic Fibrosis): Diagnosis of cystic fibrosis AND patient passed the Bronchitol Tolerance Test (BTT)

    Prescribed by pulmonologist or CF center specialist; age ≥18 years for initial therapy; initial 6 months, reauth 12 months with clinical benefit documented

    Cablivi criteria

    Cablivi (aTTP): Diagnosis of acquired thrombotic thrombocytopenic purpura (aTTP) AND first dose administered IV by HCP AND used with immunosuppressive therapy AND either given with plasma exchange or within 59 days after last plasma exchange

    Prescribed by/consult with hematologist/oncologist; coverage 3 months

    Cerdelga criteria

    Cerdelga (Gaucher disease): Diagnosis of Gaucher disease type 1 AND documented CYP2D6 metabolizer status (EM/IM/PM) by an FDA-cleared test

    Patient age ≥18 years; coverage 12 months

    Chenodal (Gaucher disease) — all medically-accepted indications

    Covered when ALL of the following are met:

    Gaucher disease criteria: Diagnosis of Gaucher disease type 1 AND patient is an extensive, intermediate, or poor metabolizer of CYP2D6 as detected by an FDA-cleared test

    Age 18 or older; coverage duration 12 months

    Chenodal (radiolucent gallstones)

    Covered when ALL of the following are met:

    Radiolucent gallstones criteria: Diagnosis of radiolucent gallstones AND well-opacifying gallbladder on oral cholecystography AND trial/failure/contraindication/intolerance to ursodiol AND patient not a candidate for surgery AND stones are not calcified or radiopaque pigment stones

    Prescribed by or in consultation with gastroenterologist; initial and reauth coverage 12 months

    Ciclopirox Nail Lacquer (Onychomycosis)

    Covered when ALL of the following are met:

    Onychomycosis criteria: No lunula involvement AND diagnosis of onychomycosis confirmed by KOH, culture, or histology AND if toenail, mild–moderate disease with ≥1 target toenail AND prior trial and failure/contraindication/intolerance to oral terbinafine (fingernails: ≥6 weeks; toenails: ≥12 weeks)

    Coverage duration 48 weeks

    Cinryze (HAE prophylaxis)

    Covered when ALL of the following are met:

    HAE diagnostic pathways: Either: (1) Low C4 AND C1-INH deficiency/dysfunction documented by low antigenic OR functional C1-INH (Type I/II), OR (2) Normal C4 and C1-INH with pathogenic mutation detected by FDA/CLIA test OR confirmed family history (HAE-nl-C1INH)

    Not used with other prophylactic treatments; initial age ≥6 years; prescriber immunologist/allergist; coverage 12 months

    Cosentyx products (psoriasis, PsA, AS, nr-axSpA, ERA, HS)

    Covered when indication-specific criteria are met:

    Plaque psoriasis initial: Diagnosis of moderate to severe plaque psoriasis with ≥3% BSA, severe scalp, or palmoplantar/facial/genital involvement AND trial and failure/CI/intolerance to at least one topical therapy (4-week minimum)

    Prescribed by or in consultation with dermatologist; initial coverage 6 months

    Psoriatic Arthritis initial: Diagnosis of active PsA with inflamed joints, dactylitis, enthesitis, axial disease, or active skin/nail involvement

    Prescribed by rheumatologist or dermatologist; initial coverage 6 months

    Ankylosing Spondylitis initial: Diagnosis of active AS AND minimum 1-month trial and failure/CI/intolerance to one NSAID at maximally tolerated doses1 month

    Prescribed by rheumatologist; initial coverage 6 months

    Cosentyx INJ 125MG/5ML specific step requirements

    Additional step therapy requirements for certain presentations:

    PsA/AS step: Either trial and failure/CI/intolerance to two listed alternative agents (eg, Cosentyx SC, Enbrel, formulary adalimumab, Orencia, Otezla, Skyrizi, formulary ustekinumab, Rinvoq, Xeljanz/XR) OR continuation of prior therapy

    Initial coverage 6 months

    Pyrimethamine (Toxoplasmosis)

    Covered when ALL of the following are met

    Pyrimethamine for toxoplasmosis criteria: Either: (1) Active treatment of toxoplasmosis (including toxoplasmic encephalitis, ocular toxoplasmosis), secondary prophylaxis, or congenital toxoplasmosis; OR (2) primary prophylaxis when TMP‑SMX intolerance documented and failed desensitization or life‑threatening prior reaction to TMP‑SMX; AND prescribed by or in consultation with infectious disease specialist

    Coverage duration 12 months; use for malaria treatment/prophylaxis is excluded

    Deferasirox

    Covered when ALL of the following are met

    Chronic iron overload due to transfusions (initial): Diagnosis of chronic transfusional iron overload AND baseline ferritin >1,000 mcg/L AND transfusion history ≥100 mL/kg packed RBCsferritin > 1000 mcg/L

    Age ≥2 years for transfusional indication; coverage 12 months; reauth requires reduction from baseline in ferritin or LIC

    NTDT initial: Diagnosis of non-transfusion-dependent thalassemia with LIC ≥5 mg Fe/g dw AND serum ferritin >300 mcg/LLIC ≥5 mg Fe/g dw

    Age ≥10 years; initial 6 months; reauth when LIC ≥3 mg Fe/g dw with reduction from baseline

    Diacomit (Stiripentol) for Dravet Syndrome

    Covered when ALL of the following are met

    Diacomit criteria: Diagnosis of seizures associated with Dravet syndrome AND used in combination with clobazam AND patient weight ≥7 kgweight ≥7 kg

    Age ≥6 months; prescribed by or in consultation with neurologist; coverage 12 months

    Doptelet (Avatrombopag)

    Covered when criteria specific to indication are met

    TPPP and ITP indications: TPPP: chronic liver disease with baseline platelets <50,000/mcL scheduled for procedure (coverage 1 month); ITP (initial): chronic/relapsed/refractory or persistent pediatric ITP with baseline platelets <30,000/mcL AND TF/C/I to corticosteroids, IVIG, or splenectomyplatelets <50,000 or <30,000

    Prescribed by or in consultation with hematologist/oncologist; ITP coverage 12 months; prereq Part D drug required

    Dupixent (dupilumab) — multiple indications

    Covered when ALL disease-specific criteria are met

    Eosinophilic Asthma (EA): Moderate-to-severe asthma with eosinophilic phenotype (baseline blood eosinophils ≥150 cells/mcL) AND ≥2 exacerbations requiring systemic corticosteroids in past 12 months OR prior asthma-related hospitalization in past 12 monthseosinophils ≥150 cells/mcL

    Age and controller therapy requirements apply; initial 6 months, reauth 12 months; prescribed by pulmonologist or allergist/immunologist

    Eosinophilic Esophagitis (EoE): Symptoms of esophageal dysfunction AND ≥15 intraepithelial eosinophils per high power field AND exclusion of other causes AND TF/C/I to an 8‑week PPI or topical esophageal corticosteroid≥15 eos/hpf

    Patient weight ≥15 kg; initial 12 months; reauth requires clinical/histologic/endoscopic improvement; prescribe by gastroenterologist or allergist/immunologist

    Atopic Dermatitis (AD): Moderate-to-severe AD with ≥10% BSA or SCORAD ≥25 AND TF/C/I to appropriate topical/systemic therapiesBSA ≥10% or SCORAD ≥25

    Age limits and prescriber restrictions apply; initial 6 months, reauth 12 months

    Emgality (galcanezumab) — migraine and cluster headache

    Covered when ALL indication-specific criteria are met

    Migraine indications: Episodic Migraine: ≥4 migraine days/month (120 mg strength where specified). Chronic Migraine: ≥8 migraine days/month; Episodic Cluster Headache criteria as specified. Not used in combination with another injectable CGRP inhibitor≥4 or ≥8 migraine days/month

    Age ≥18 years; initial 3–6 months depending on indication; reauth 12 months with documented response

    Empaveli (pegcetacoplan)

    Covered when ALL indication-specific criteria are met

    PNH: Diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)

    Prescribed by or in consultation with hematologist/oncologist; coverage 12 months; reauth requires clinical response

    C3G / primary IC-MPGN: Diagnosis of C3 glomerulopathy or primary immune‑complex MPGN AND patient treated with maximally tolerated ACEI/ARB or SGLT2 inhibitor for ≥12 weeks prior to initiation12 weeks

    Prescribed by nephrologist; coverage 12 months; reauth requires clinical response; prereq Part D drug required

    Enbrel (etanercept) – rheumatologic and dermatologic indications

    Covered when ALL indication-specific criteria are met

    Rheumatoid Arthritis (RA): Moderately to severely active RA AND minimum 3‑month TF/C/I to one conventional DMARD (methotrexate, leflunomide, sulfasalazine) at maximally tolerated dose3-month trial

    Prescribed by or in consultation with rheumatologist; initial 6 months, reauth 12 months with demonstrated clinical response; prereq Part D drug required

    Plaque Psoriasis: Moderate-to-severe chronic plaque psoriasis with ≥3% BSA or special-site involvement AND TF/C/I to topical therapy (minimum durations as listed)BSA ≥3%

    Prescribed/consult dermatologist; initial 6 months, reauth 12 months

    L-glutamine (for sickle cell disease)

    Covered when ALL of the following are met

    Sickle cell disease criteria: Diagnosis of sickle cell disease AND history of ≥2 painful sickle cell crises within past 12 months≥2 painful crises in past 12 months

    Coverage 12 months; reauth requires documented clinical response

    Rheumatology and dermatology biologics

    Coverage depends on indication-specific requirements; examples extracted below reflect the logical criteria for selected products in this segment.

    Rheumatology biologics (RA, PJIA, AS, PsA): Prescribed by or in consultation with appropriate specialist AND prerequisite Part D drug use where required AND initial approval typically 6 months with reauth 12 months requiring documented clinical response

    See specific product entries for required prior therapy durations (eg, 3 months RA, 6 weeks PJIA)

    Evrysdi (risdiplam) criteria

    Evrysdi (SMA) initial/reauth criteria:

    Evrysdi initial therapy: Diagnosis of SMA type I–III with 5q SMN1 mutation/deletion or compound heterozygous mutation AND at least 2 copies of SMN2 AND baseline standardized motor exam performed (HINE‑2, HFMSE, RULM, CHOP‑INTEND, MFM‑32, or Bayley item 22) AND not receiving concomitant chronic SMN‑modifying therapy

    Prescribed/consult neurologist with SMA expertise; initial and reauth duration 12 months; prior gene therapy allowed only if documented inadequate response

    Fasenra criteria

    Fasenra (benralizumab) asthma/EGPA criteria:

    Asthma initial criteria: Severe eosinophilic asthma defined by baseline eosinophils ≥150 cells/µL AND either ≥2 exacerbations requiring systemic corticosteroids in past 12 months OR prior asthma‑related hospitalization in past 12 monthseosinophils >=150 cells/µL

    Age and controller therapy requirements vary by age group; initial 6 months, reauth 12 months; prescribed/consult pulmonologist or allergist/immunologist

    EGPA initial criteria: Diagnosis of eosinophilic granulomatosis with polyangiitis AND currently receiving corticosteroid therapy unless contraindicated

    Prescribed/consult pulmonologist, rheumatologist, or allergist/immunologist; approval 12 months

    Icatibant criteria

    Icatibant (HAE) criteria:

    HAE attack treatment: Diagnosis of hereditary angioedema confirmed by either low C4 plus C1‑INH deficiency/dysfunction (antigenic or functional) OR normal C4/C1‑INH with pathogenic gene mutation or confirmed family history; for acute HAE attacks; not used in combination with other approved acute HAE treatments

    Prescriber immunologist/allergist required; initial and reauth coverage 12 months

    Procrit criteria

    Erythropoiesis-stimulating agents (Procrit) criteria highlights:

    Anemia with CKD: Diagnosis of CKD with anemia meeting lab thresholds (Hct <30% or Hgb <10 g/dL for specified settings) AND adequate iron stores (ferritin >100 mcg/L AND TSAT >20%)Hgb/Hct thresholds and iron indices

    Initial coverage varies by indication (eg, 6 months CKD); reauth 12 months; off‑label uses not approved if Hgb >10 g/dL or Hct >30%

    Other indications: Indication‑specific lab thresholds and prior therapy requirements apply (chemotherapy‑related, MDS, HCV, preop) with coverage durations as listed

    See product entry for details

    Initial therapy for hereditary angioedema (HAE)

    HAE — initial treatment criteria

    HAE initial diagnosis: Diagnosis of hereditary angioedema (HAE) with one of the diagnostic pathways below

    Not used in combination with other approved treatments for acute HAE

    Pathway A: Both: (a) C4 below LLN AND (b) C1‑INH deficiency/dysfunction documented by low antigenic OR functional C1‑INH level
    Pathway B (HAE‑nl‑C1INH): Both: (a) Normal C4 and normal C1‑INH levels AND (b) either pathogenic mutation detected by FDA/CLIA test OR confirmed family history of recurrent angioedema

    Age ≥18 for initial therapy; prescriber immunologist/allergist; coverage 12 months; reauth requires positive clinical response

    Initial therapy criteria for biologic/immunomodulatory agents

    Biologic agents (example: Humira) — indication-specific initial criteria

    General precondition: Diagnosis matching the specific indication (RA, PJIA, PsA, PsO, AS, CD, UC, HS, uveitis) AND prescriber specialty as specified

    Prescriber restrictions vary by indication

    RA requirement: Moderately to severely active RA AND minimum 3‑month TF/C/I to one conventional therapy (methotrexate, leflunomide, or sulfasalazine) at maximally tolerated doses3 months

    Reauth requires evidence of positive clinical response

    PJIA requirement: Moderately to severely active PJIA AND minimum 6‑week TF/C/I to leflunomide or methotrexate at maximally tolerated doses6 weeks

    Reauth requires clinical response evidence

    Psoriasis requirement: Plaque psoriasis with ≥3% BSA or special‑site involvement AND trial/failure of topical therapy (minimum 30 days; 14 days for topical corticosteroids)30 days (topical) or 14 days (topical corticosteroids)

    Reauth requires reduction in BSA or symptom improvement

    AS requirement: Active ankylosing spondylitis AND minimum 1‑month TF/C/I to an NSAID at maximally tolerated doses1 month

    Reauth requires documented clinical response

    CD requirement: Moderately to severely active Crohn's disease with clinical features OR CDAI >220CDAI > 220

    Reauth requires evidence of improved intestinal inflammation or labs

    Growth hormone product coverage criteria

    Growth hormone products (Genotropin) — diagnostic and monitoring criteria

    General: Indication‑specific diagnostic criteria (PGHD, PWS, GFSGA, SHOX, ISS, AGHD, etc.) and required testing/documentation per indication

    Prescribed by or in consultation with endocrinologist for most indications; coverage 12 months; reauth may require evidence of response

    Bone age limits: For pediatric GH indications document male bone age <16 years or female bone age <14 years where requiredmale BA <16y, female BA <14y
    Stimulation testing for AGHD/IGHD: Adult GHD requires GH stimulation testing (ITT, glucagon, macimorelin) with specified peak GH cutoffs to confirm diagnosis; reauth requires IGF‑1 monitoring within past 12 monthsITT <=5 mcg/L; glucagon <=3 mcg/L; macimorelin <=2.8 ng/mL

    Targeted oncology therapy criteria

    Oncology-targeted therapies — diagnostic biomarker requirement

    RET fusion-positive tumors (example: Gavreto): Diagnosis of RET fusion‑positive tumor detected by FDA‑approved or CLIA test AND disease advanced/metastatic requiring systemic therapy

    Coverage duration 12 months; continuation of prior therapy approved

    HER2‑mutant NSCLC (example: Hernexeos/Hyrnuo): Diagnosis of NSCLC with HER2 activating mutation detected by FDA‑approved or CLIA test; prior systemic therapy required for some products

    Coverage duration 12 months

    Inflectra initial - Crohn's Disease

    Inflectra (examples of initial coverage criteria by indication): Covered when ALL of the following are met

    Inflectra - Crohn's Disease (initial): Diagnosis of moderately to severely active Crohn's disease or fistulizing Crohn's with clinical features (frequent diarrhea/abdominal pain, ≥10% weight loss, complications, abnormal labs) OR CDAI >220 AND TF/C/I to one of: 6‑mercaptopurine, azathioprine, corticosteroids, methotrexateCDAI > 220

    Prescribed/consult gastroenterologist; initial 6 months; reauth requires clinical response

    Inflectra initial - Ulcerative Colitis

    Inflectra (Ulcerative colitis initial): Covered when ALL of the following are met

    Inflectra - Ulcerative Colitis (initial): Diagnosis of moderately to severely active UC with objective features (>6 stools/day, frequent blood, urgency, ulcers, abnormal labs) OR corticosteroid‑dependent/refractory disease AND TF/C/I to corticosteroids and aminosalicylates or azathioprine/6‑MP as specified

    Prescribed/consult gastroenterologist; initial 6 months; reauth 12 months

    Reauthorization response criteria

    Reauthorization criteria (examples across listed inflammatory indications): Covered for continuation when ANY of the following indicate positive clinical response

    RA reauth: Reduction in total active (swollen and tender) joint count from baseline OR improvement in symptoms (pain, stiffness, inflammation)improvement vs baseline

    Evidence required at reauthorization

    Psoriasis reauth: Reduction in BSA involvement OR improvement in symptoms (eg, pruritus, inflammation)improvement vs baseline
    CD/UC reauth: Improvement in intestinal inflammation (eg, mucosal healing, improved CRP/ESR/platelet count) OR reversal of high fecal output stateimprovement vs baseline

    Prescriber & duration rules

    Prescriber restrictions: Specified indications must be prescribed by or in consultation with appropriate specialists (eg, rheumatologist for RA/AS/PsA; gastroenterologist for CD/UC; dermatologist for psoriasis)
    Coverage duration: Initial uses generally: 6 months; reauthorization: 12 months (Inflectra example)6 months initial, 12 months reauth

    Breast cancer — PIK3CA-mutated, HR+, HER2-

    Example: Alpelisib (implicit from PIK3CA criteria) — covered when ALL of the following are met

    Breast cancer PIK3CA‑mutated criteria: Locally advanced or metastatic HR‑positive, HER2‑negative breast cancer AND tumor PIK3CA‑mutated by FDA‑cleared or CLIA test AND used following recurrence on or after adjuvant endocrine therapy AND used in combination with palbociclib and fulvestrant

    Coverage 12 months; prerequisite Part D drug required

    Itraconazole

    Itraconazole indications: Systemic fungal infection OR fingernail onychomycosis (confirmed by KOH/culture/biopsy) with TF/C/I to oral terbinafine (≥6 weeks fingernail) OR toenail onychomycosis with TF/C/I to terbinafine (≥12 weeks)

    Coverage durations vary by indication (SFI 6 months; fingernail 5 weeks; toenail 3 months); prereq Part D drug required

    Immune globulin (IVIG/SCIG) criteria

    Immune globulin (IVIG/SCIG) — initial and renewal coverage

    IVIG initial criteria: IV administration for listed diagnoses (primary immunodeficiencies, selected secondary antibody deficiencies, hematologic autoimmune disorders, neuromuscular autoimmune disorders) with immunologic evaluation (eg, low IgG for age, inadequate vaccine response) and TF/C/I to listed therapies where applicableAdminister at minimum effective dose and frequency

    Coverage typically 12 months (4 months for solid organ transplant); prescriber with expertise in IG therapy

    IVIG reauthorization: For non‑oncology renewal, patient has objective improvement on therapy and plan to administer at minimum effective dose (dose/frequency adjustment)

    Subject to Part B vs Part D review

    Jynarque (tolvaptan) criteria

    Tolvaptan (Jynarque) — ADPKD criteria

    Initial ADPKD: Diagnosis of rapidly progressing autosomal dominant polycystic kidney disease AND liver tests (ALT, AST, bilirubin) monitored per schedule (baseline, 2 and 4 weeks, then monthly for first 18 months, then at least every 3 months thereafter if >18 months) AND no history of significant liver impairment

    Coverage 12 months; reauth requires positive clinical response or absence of hepatic injury signs

    Kerendia criteria

    Kerendia (finerenone) — CKD with T2D and HF with LVEF ≥40%

    CKD with T2D initial: CKD associated with T2D with UACR ≥30 mg/g AND eGFR ≥25 mL/min/1.73 m2 AND serum potassium ≤5.0 mEq/L AND either trial of a maximally tolerated ACE inhibitor or ARB for 30 days or documented contraindication/intolerance

    Coverage 12 months; reauth requires continued ACE/ARB or documented intolerance and evidence of response

    HF with LVEF ≥40% initial: Diagnosis of heart failure with LVEF ≥40% and NYHA II–IV AND eGFR ≥25 AND serum potassium ≤5.0 mEq/L AND on diuretic treatment for ≥30 days AND not on MRA combination; either on SGLT2 inhibitor or has contraindication to SGLT2 inhibitor

    Coverage 12 months; prescribe/consult cardiologist for HF indication; reauth requires response

    Kesimpta criteria

    Kesimpta (ofatumumab) — MS criteria

    MS initial: Diagnosis of a relapsing form of multiple sclerosis AND trial and failure (minimum 4‑week supply), contraindication, or intolerance to one disease‑modifying therapy OR continuation of prior therapy

    Not used in combination with another DMT or B‑cell targeted therapy; prescribed/consult neurologist; coverage 12 months; reauth requires positive clinical response

    Kineret criteria

    Kineret (anakinra) — RA, NOMID, DIRA criteria

    RA initial: Moderately to severely active RA AND either TF/C/I to two specified biologic/targeted agents OR attestation that trial is inappropriate OR continuation of prior therapy

    Initial 6 months; reauth 12 months with documented clinical response; prescriber rheumatologist

    NOMID initial: Diagnosis of neonatal‑onset multisystem inflammatory disease confirmed by NLRP3 mutation OR clinical criteria (two clinical symptoms plus elevated acute phase reactants)

    Initial 6 months; reauth 12 months with positive clinical response; prescriber allergist/immunologist, rheumatologist, or pediatrician

    Other specialty drug criteria

    Miscellaneous oncology and specialty drug entries (examples)

    Iwilfin (neuroblastoma): High‑risk neuroblastoma with at least partial response to prior multiagent therapy including prior anti‑GD2 immunotherapy

    Coverage 12 months; continuation of prior therapy approved; prereq Part D drug may be required

    Jakafi: Indications include myelofibrosis, polycythemia vera after TF/C/I to hydroxyurea, steroid‑refractory aGVHD, cGVHD after failure of systemic therapies

    Coverage 12 months; prereq Part D drug required

    Mifepristone for Cushing's: Endogenous Cushing's syndrome with type 2 diabetes or glucose intolerance AND failed or ineligible for surgery AND not pregnant

    Prescribed/consult endocrinologist; initial/reauth 6 months; reauth requires improved or stable glucose tolerance

    Komzifti (general)

    Komzifti

    Komzifti coverage: Diagnosis of AML with susceptible NPM1 mutation detected by FDA‑approved or CLIA test; used in approved indications

    Coverage duration 12 months; continuation of prior therapy approved

    Mifepristone - Cushing's

    Mifepristone 300 mg (Cushing's syndrome)

    Initial Cushing's criteria: Endogenous Cushing's syndrome with type 2 diabetes or glucose intolerance AND failed or not candidate for surgery AND patient not pregnant

    Prescribed/consult endocrinologist; initial/reauth 6 months; reauth requires improved or stable glucose tolerance

    Krazati (KRAS G12C)

    Krazati

    KRAS G12C indications: Locally advanced or metastatic NSCLC or CRC with KRAS G12C mutation detected by FDA‑approved or CLIA test AND prior systemic therapy as specified (CRC: combination with cetuximab and prior chemotherapies)

    Coverage 12 months; prereq Part D drug required for some indications

    PKU - Sapropterin

    Sapropterin / Zelvysia

    PKU initial: Diagnosis of phenylketonuria (PKU) AND monitoring of blood phenylalanine after 1 week and periodically up to 2 months to assess response

    Initial coverage 2 months; reauth 12 months with documented clinical response

    Lenvima (various cancer indications)

    Lenvima

    Indications covered: Differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, advanced endometrial carcinoma (pMMR) with progression after systemic therapy as specified; use in combination with pembrolizumab or everolimus where required

    Coverage 12 months; some regimens require prior Part D drug

    Ambrisentan - PAH

    Ambrisentan

    PAH initial: Diagnosis of symptomatic pulmonary arterial hypertension confirmed by right heart catheterization OR patient currently on PAH therapy

    Prescribed/consult pulmonologist or cardiologist; initial 6 months, reauth 12 months; reauth requires positive clinical response

    Livmarli (ALGS, PFIC)

    Livmarli

    ALGS initial: Diagnosis of Alagille syndrome with molecular confirmation of JAG1 or NOTCH2 mutation AND cholestatic pruritus AND inadequate response to one pruritus therapy (eg, rifampin)

    Age and prescriber restrictions apply; initial 12 months; reauth requires clinical response

    PFIC initial: Diagnosis of PFIC with molecular confirmation of specified genes (ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, MYO5B) AND cholestatic pruritus AND inadequate response to one pruritus therapy

    Prescriber hepatologist/gastroenterologist; initial 6 months, reauth 12 months

    Lonsurf - metastatic GI cancers

    Lonsurf (trifluridine/tipiracil)

    mCRC: Metastatic colorectal cancer with prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy AND anti‑VEGF therapy; for RAS wild‑type, prior anti‑EGFR therapy required when applicable

    Coverage 12 months; prereq Part D drug required

    Gastric/GJ adenocarcinoma: Metastatic gastric or gastroesophageal junction adenocarcinoma with prior treatment with two specified regimens

    Coverage 12 months

    Lynparza

    Lynparza

    PARP indications: Epithelial ovarian/fallopian tube/primary peritoneal cancer, breast, pancreatic, or prostate indications as per FDA labeling

    Coverage 12 months; continuation of prior therapy approved

    Lytgobi (FGFR2 fusion)

    Lytgobi

    Intrahepatic cholangiocarcinoma: Unresectable/locally advanced/metastatic intrahepatic cholangiocarcinoma with FGFR2 fusion or rearrangement AND prior systemic therapy

    Coverage 12 months; prereq Part D drug required

    Dronabinol (CINV, AIDS anorexia)

    Dronabinol

    CINV: Patient receiving cancer chemotherapy AND TF/C/I to a 5‑HT3 antagonist AND TF/C/I to one of listed antiemetics (eg, prochlorperazine, dexamethasone, haloperidol, olanzapine)

    Coverage for CINV 6 months; subject to Part B vs Part D review

    AIDS anorexia: Diagnosis of anorexia with weight loss in patient with AIDS on antiretroviral therapy

    Coverage 12 months

    Mavyret - HCV

    Mavyret

    Hepatitis C: Applied consistent with current AASLD/IDSA guideline: diagnosis of hepatitis C (or transplant from HCV+ donor), WITHOUT decompensated liver disease (not Child‑Pugh B/C) AND not used with another HCV DAA

    Coverage 8–16 weeks; prescriber hepatologist/gastroenterologist/infectious disease/HIV specialist as specified

    Mayzent - MS

    Mayzent

    MS initial: Diagnosis of relapsing form of multiple sclerosis AND not used in combination with another disease‑modifying therapy for MS

    Prescribed/consult neurologist; coverage 12 months; reauth requires clinical response

    Mekinist (BRAF-mutant indications)

    Mekinist (trametinib)

    BRAF V600E/K mutant cancers: Unresectable/metastatic melanoma, adjuvant melanoma with nodal involvement, metastatic NSCLC, ATC, or other listed cancers when BRAF V600E or V600K mutation detected by FDA‑approved or CLIA test; use in combination with dabrafenib where specified

    Coverage 12 months

    MS initial/reauth criteria

    Multiple Sclerosis (various injectable and disease-modifying therapies)

    MS initial therapy: Diagnosis of a relapsing form of MS AND prescribed by or in consultation with a neurologist AND not used in combination with another DMTcoverage duration 12 months

    Some agents require trial of other interferons for initial approval per product

    BRAF-mutant cancer therapy

    BRAF-mutant oncology agents (e.g., Mekinist, Mektovi, other BRAF combos)

    Oncology BRAF: Diagnosis of indicated cancer AND tumor BRAF V600E or V600K mutant per FDA‑approved or CLIA test AND medication used in combination with indicated companion agent when specifiedcoverage duration 12 months

    Continuation of prior therapy approved when criteria met

    Migraine acute therapy

    Acute migraine: dihydroergotamine solution

    Dihydroergotamine (acute migraine): Diagnosis of migraine for acute treatment AND trial and failure or intolerance to one triptan OR contraindication to all triptans

    Coverage initial/reauth 12 months; reauth requires positive response

    T2DM therapy

    Mounjaro (tirzepatide) — type 2 diabetes mellitus

    Mounjaro initial criteria: Medical records confirming diagnosis of type 2 diabetes mellitus OR lab evidence (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hr OGTT ≥200 mg/dL)

    Coverage 12 months; reauth requires clinical response

    Nucala indications and criteria

    Nucala (mepolizumab) — multiple eosinophilic indications

    Asthma (init): Severe eosinophilic asthma with baseline blood eosinophils ≥150 cells/µL OR ≥300 cells/µL in past 12 months AND history of ≥2 exacerbations requiring systemic corticosteroids or prior asthma‑related hospitalization in past 12 monthscoverage init 6 months, reauth 12 months

    Prescribed/consult pulmonologist or allergist/immunologist; reauth requires positive clinical response

    HES (init): Diagnosis of hypereosinophilic syndrome for ≥6 months AND secondary causes ruled out AND FIP1L1‑PDGFRA negative AND pre‑treatment eosinophils ≥1000 cells/µL AND TF/C/I to corticosteroids or cytotoxic/immunosuppressive therapypre‑treatment eos ≥1000 cells/µL

    Coverage 12 months; reauth requires positive clinical response

    COPD (init): COPD with Type 2 inflammation (blood eosinophils ≥150 cells/µL baseline OR ≥300 cells/µL in past 12 months) AND receiving triple therapy (ICS+LAMA+LABA) OR LAMA+LABA if ICS contraindicated AND ≥2 exacerbations requiring systemic corticosteroids or COPD‑related hospitalization in past 12 monthsas stated

    Initial 6 months, reauth 12 months; reauth requires clinical response

    G-CSF prophylaxis/treatment

    Neulasta (pegfilgrastim) — febrile neutropenia prophylaxis/treatment

    FN prophylaxis/treatment: Patient receiving chemotherapy with FN risk per criteria (dose‑dense regimens, >20% FN risk, or 10–20% with additional risk factors) OR treatment of FN; prescribed/consult hematologist/oncologistcoverage duration per indication

    Specific protocols and risk factors listed in policy

    HES (initial)

    Hypereosinophilic Syndrome (HES) — Initial

    HES initial criteria: Diagnosis of HES for ≥6 months AND secondary causes excluded AND FIP1L1‑PDGFRA negative AND pre‑treatment blood eosinophils ≥1000 cells/µL AND TF/C/I to corticosteroids or cytotoxic/immunosuppressivesas stated

    Coverage 12 months; reauth requires positive clinical response

    HES/EGPA/CRSwNP (reauth)

    HES (reauth) / EGPA, CRSwNP reauth

    Reauthorization: Patient demonstrates positive clinical response to therapy (indication‑specific measures)clinical response

    Applies to HES, EGPA, CRSwNP

    COPD (initial)

    COPD — Initial

    COPD initial criteria: Diagnosis of COPD AND evidence of Type 2 inflammation (blood eosinophils ≥150 cells/µL baseline OR ≥300 cells/µL in last 12 months) AND receiving triple therapy (ICS+LAMA+LABA) OR if ICS contraindicated LAMA+LABA AND ≥2 exacerbations requiring systemic corticosteroids or COPD‑related hospitalization in past 12 monthsas stated

    Initial 6 months; reauth 12 months with positive clinical response

    Odactra (initial)

    House Dust Mite Allergic Rhinitis — Odactra (initial)

    Odactra initial criteria: Diagnosis of HDM‑induced allergic rhinitis AND positive in vitro or skin test to D. farinae or D. pteronyssinus AND TF/C/I to an intranasal corticosteroid AND an antihistamine

    Age 5–65; prescribed/consult allergist/immunologist; coverage 12 months

    IPF (initial)

    Idiopathic Pulmonary Fibrosis (IPF) — Ofev (initial)

    IPF initial criteria: Diagnosis of IPF with exclusion of other causes of ILD AND HRCT showing UIP or probable UIP pattern (if no surgical biopsy) OR HRCT plus surgical lung biopsy consistent with IPFimaging/biopsy pattern

    Prescribed/consult pulmonologist or rheumatologist; coverage 12 months

    Chronic Fibrosing ILD / PPF (initial)

    Chronic Fibrosing ILD with Progressive Phenotype — Ofev (initial)

    Chronic fibrosing ILD initial criteria: Diagnosis of chronic fibrosing ILD or progressive pulmonary fibrosis AND HRCT showing fibrotic features AND evidence of progressive phenotype (decline in FVC, worsening symptoms, or increased fibrosis on imaging)

    Prescribed/consult pulmonologist; coverage 12 months

    hATTR amyloidosis (initial)

    hATTR Amyloidosis with Polyneuropathy — Onpattro (initial)

    hATTR initial criteria: Diagnosis of hATTR amyloidosis with polyneuropathy AND pathogenic TTR mutation detected by FDA‑approved or CLIA test AND baseline neurologic scores meeting criteria (PND ≤ IIIb OR FAP stage 1–2 OR NIS 5–130) AND clinical signs of peripheral/autonomic neuropathyneurologic scores as stated

    Prescribed/consult neurologist; not used in combination with TTR silencer or stabilizer; coverage 12 months

    Orencia (initial)

    Rheumatoid Arthritis / PJIA / Psoriatic Arthritis — Orencia (initial)

    RA/PJIA/PsA initial criteria: RA: moderately to severely active disease AND minimum 3‑month TF/C/I to one conventional therapy (methotrexate, leflunomide, sulfasalazine). PJIA: minimum 6‑week TF/C/I to methotrexate or leflunomide. PsA: active disease with inflamed joints/dactylitis/enthesitis/axial disease or active skin/nail involvementtrial durations as stated

    Prescriber rheumatologist for RA/PJIA; initial 6 months; reauth 12 months requiring documented clinical response

    Reauthorization (general)

    Reauthorization requirements (multiple drugs)

    Reauth general requirement: Patient demonstrates positive clinical response to therapy as evidenced by indication‑specific measures (eg, reduced swollen/tender joint count, symptom improvement, reduction in BSA for psoriasis)clinical response

    Applies broadly across listed products for reauth

    Nurtec (initial)

    Nurtec (migraine) — initial

    Nurtec initial criteria: Diagnosis of migraine AND for acute treatment TF/C/I to one triptan or contraindication to all triptans; not used with another CGRP inhibitor≥1 triptan failure or contraindication

    Age ≥18 for initial; coverage durations per indication

    Orenitram (PAH) initial and reauthorization

    Covered when ALL of the following are met for initial therapy or reauthorization as specified.

    Initial Diagnosis: Diagnosis of pulmonary arterial hypertension (PAH) AND PAH is symptomatic

    Diagnosis must be confirmed by right heart catheterization OR patient is currently on PAH therapy

    Prescriber: Prescribed by or in consultation with a pulmonologist or cardiologist

    Coverage duration: initial 6 months, reauth 12 months

    Reauthorization response: Patient demonstrates positive clinical response to therapy as evidenced by disease‑specific measures

    Applies to disease‑specific reauth as described

    Orkambi (Cystic Fibrosis)

    Covered when ALL of the following are met.

    Genotype: Patient is homozygous for the F508del CFTR mutation confirmed by FDA‑cleared or CLIA‑approved test

    Patient age ≥6 years for initial therapy; prescriber CF care center specialist or pulmonologist; coverage 12 months; reauth requires benefit (improved FEV1 or fewer exacerbations)

    Otezla (PsA, plaque psoriasis, Behcet's oral ulcers)

    Covered when ALL applicable indication-specific criteria are met.

    Psoriatic arthritis: Diagnosis of active PsA with clinically inflamed joints, dactylitis, enthesitis, axial disease, or active skin/nail involvement

    Prescribed/consult dermatologist or rheumatologist; initial 6 months, reauth 12 months with documented clinical response

    Plaque psoriasis: Diagnosis of plaque psoriasis AND TF/C/I to at least one 4‑week topical therapy (14 days for topical corticosteroids) AND patient weight ≥20 kg

    Prescribed/consult dermatologist; initial 6 months; reauth requires response

    Behcet's oral ulcers: Diagnosis of Behcet's disease with active oral ulcers

    Initial 6 months; reauth requires clinical response

    Ozempic (Diabetes and MASH)

    Covered when ALL applicable criteria are met for the indicated condition.

    T2DM initial: Ongoing treatment of type 2 diabetes mellitus with documentation of diagnosis via chart notes or lab criteria (A1c ≥6.5% OR FPG ≥126 mg/dL OR 2‑hr OGTT ≥200 mg/dL)

    Coverage 12 months; reauth requires demonstration of positive clinical response

    MASH initial: Diagnosis of metabolic dysfunction‑associated steatohepatitis (MASH) without cirrhosis confirmed by FAST, MAST, or liver biopsy AND fibrosis stage F2 or F3 documented by FibroScan, FIB‑4, or equivalent

    Prescribed/consult gastroenterologist, endocrinologist, or hepatologist; coverage 12 months; reauth requires positive response

    Diclofenac topical (Osteoarthritis of knees)

    Covered when ALL of the following are met.

    Diagnosis of osteoarthritis of the knees
    Prior therapy: Either TF/C/I to at least two prescription‑strength topical or oral NSAIDs OR history of peptic ulcer disease/GI bleed OR age >65 with one additional GI risk factor

    Initial and reauth coverage 12 months; reauth requires positive clinical response

    Eltrombopag (ITP, chronic hepatitis C thrombocytopenia, SAA)

    Covered when ALL applicable diagnosis-specific criteria are met.

    ITP initial: Diagnosis of chronic/relapsed/refractory or persistent ITP with baseline platelets <30,000/mcL AND TF/C/I to corticosteroids, IVIG, or splenectomy

    Prescribed/consult hematologist/oncologist; coverage 12 months; reauth requires platelet response sufficient to avoid bleeding

    First‑line SAA: Severe aplastic anemia meeting ≥2 hematologic thresholds AND used in combination with standard immunosuppressive therapy

    Coverage 6 months for first‑line SAA

    Modafinil (OSA, SWD, Narcolepsy, MS fatigue, depression adjunct, idiopathic hypersomnia)

    Covered when ALL applicable indication-specific criteria are met.

    OSA initial: Diagnosis of OSA defined by ≥15 obstructive respiratory events/hour OR ≥5 events/hour PLUS qualifying symptoms; sleep study documentation required unless justified

    Coverage and durations per indication; reauth requires positive clinical response

    Shift‑work disorder: Diagnosis of SWD with symptoms ≥3 months associated with work period and exclusion of other causes

    Coverage per policy; reauth requires clinical response

    Retacrit — Initial and Reauthorization

    Retacrit (erythropoiesis‑stimulating agent) covered when criteria below are met

    Retacrit initial/re‑auth criteria: Diagnosis matching listed indication (CKD, HIV, chemo‑induced anemia, MDS, preop) AND adequate iron stores when indicated (ferritin >100 mcg/L AND TSAT >20%) AND lab criteria for anemia met per indication AND patient demonstrates positive clinical response for reauthsee thresholds

    Off‑label uses (except MDS, HCV) not approved if Hgb >10 g/dL or Hct >30%

    Retevmo — Targeted therapy

    Retevmo covered when ALL of the following are met

    Retevmo criteria: Diagnosis of RET fusion‑positive NSCLC, MTC, thyroid cancer, or solid tumor as appropriate AND RET gene fusion/mutation detected by FDA‑approved or CLIA test AND disease advanced/metastatic requiring systemic therapy AND progressed on prior systemic treatment or no satisfactory alternative treatments

    Coverage 12 months; approve continuation of prior therapy

    Rinvoq — Immunomodulator/JAK inhibitor

    Rinvoq (and Rinvoq Lq) covered when criteria below are met

    Indications list: Covered indications include RA, PJIA, PsA, AS, nr‑axSpA, CD, UC, AD, GCA with indication‑specific required informationnone

    Prescriber specialty and prior therapy requirements apply per indication

    Step/Prerequisite therapy: For many indications patient must have inadequate response/intolerance to specified conventional therapies and/or TNF inhibitor trials before initiation; not used in combination with other JAK inhibitors, biologic DMARDs, or potent immunosuppressantsnone

    Initial authorization typically 6 months; reauth 12 months with evidence of positive clinical response

    Rinvoq Lq — Pediatric/psoriatic arthritis details

    Rinvoq Lq (liquid) specific criteria

    Rinvoq Lq criteria: PJIA and PsA indications require TF/C/I to specified conventional therapies and TNF inhibitors; prescriber specialty restrictions apply for PJIAnone

    Coverage: initial 6 months, reauth 12 months with demonstration of positive clinical response; not used with other JAK‑I or biologic DMARDs

    Oncology/specialty agents — diagnostic biomarker requirements

    Selected oncology/specialty agents covered when specified diagnostic and molecular criteria met

    Romvimza: Diagnosis of tenosynovial giant cell tumor (TGCT) AND symptomatic AND surgical resection would likely cause worsening functional limitation or severe morbiditynone

    Coverage 12 months; continuation of prior therapy approved

    Rozlytrek: Metastatic NSCLC with ROS1 rearrangement OR solid tumors with NTRK fusion detected by FDA‑approved or CLIA test AND metastatic/unresectable disease progressed after prior treatment or no satisfactory alternatives AND no known acquired resistance mutationnone

    Coverage 12 months; continuation of prior therapy approved

    Rydapt: Newly diagnosed AML with FLT3 mutation detected by FDA‑approved or CLIA test AND used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation

    Coverage 12 months; see diagnostic/regimen documentation requirements

    Rydapt — Initial therapy

    Rydapt (midostaurin) covered when ALL of the following are met

    Rydapt coverage criteria: Newly diagnosed AML with FLT3 mutation detected by FDA‑approved or CLIA test AND used in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation

    Coverage 12 months

    Vigabatrin — Indications and age limits

    Vigabatrin covered when ALL of the following are met

    Vigabatrin CPS/IS criteria: Complex partial seizures (adjunct): TF/C/I to two formulary anticonvulsants documented; infantile spasms: age 1 month to 2 years as specified

    Age limits: CPS ≥2 years; IS 1 month–2 years; coverage 12 months; prerequisite Part D drug required

    Octreotide — Initial indications

    Octreotide acetate covered when ALL of the following are met

    Octreotide — acromegaly and tumor indications: Acromegaly with inadequate response to or ineligibility for surgery/radiation AND TF/C/I to a dopamine agonist at maximally tolerated doses; OR metastatic carcinoid or VIP tumor requiring symptomatic treatment

    Coverage 12 months; reauth requires positive clinical response

    Hizentra — Initial and reauthorization

    Hizentra (SCIG) covered when ALL of the following are met

    Hizentra criteria: Diagnosis of CIDP or specified primary immunodeficiency with documented low IgG and inadequate vaccine response where applicable AND medication administered subcutaneously at minimum effective dose

    Prescribed/consult specialist; initial and reauth 12 months; reauth requires objective improvement

    Biologic therapies — dermatology and gastroenterology

    Skyrizi, Stelara, Steqeyma and similar biologics for psoriasis, PsA, CD, UC covered when ALL of the following are met

    Psoriasis/PsA criteria: Diagnosis consistent with indication (eg, plaque psoriasis ≥3% BSA or special‑site involvement; active PsA with inflamed joints/dactylitis/enthesitis/axial disease) AND TF/C/I to required topical or prior systemic therapies where specified AND prescriber specialty consultation when required

    Initial coverage often 6 months; reauth 12 months with documented clinical response

    IBD biologic induction criteria: For Crohn's disease and ulcerative colitis: moderately to severely active disease defined by symptoms and/or CDAI >220 or objective labs; some formulations require IV induction dosing per FDA label

    IV induction often one‑time or 3 months; maintenance 12 months

    Spevigo — GPP

    Spevigo covered when ALL of the following are met

    Spevigo — generalized pustular psoriasis: Diagnosis of generalized pustular psoriasis with primary sterile pustules (not plaque‑restricted) AND patient weight ≥40 kg AND age ≥12 years

    Prescribed/consult dermatologist; initial and reauth 12 months; reauth requires clinical response

    Stelara IV — Induction dosing for CD/UC

    Stelara IV induction covered when ALL of the following are met

    Stelara IV induction for IBD: Diagnosis of moderately to severely active Crohn's disease or ulcerative colitis with supporting clinical/lab features AND administration as single IV induction dose with weight‑based dosing per FDA label (260/390/520 mg based on weight)

    Induction coverage: one time per label

    No explicit exclusion criteria are listed in this excerpt for the individual products. The policy entries shown provide indication-specific coverage requirements, required medical information, age and prescriber restrictions, prior-therapy requirements, and coverage durations, but do not enumerate general exclusions for the products in this segment.

    Cerdelga (Gaucher disease) is limited to adult patients: the entry requires documented diagnosis of Gaucher disease type 1 and specifies that the patient must be 18 years of age or older. In addition, the policy requires documentation of CYP2D6 metabolizer status by an FDA‑cleared test as part of the required medical information.

    Requests for coverage of any pyrimethamine product for the treatment or prophylaxis of malaria are explicitly excluded. The policy states that coverage of pyrimethamine for malaria treatment or prophylaxis is not authorized and will not be approved; pyrimethamine coverage is limited to specified toxoplasmosis indications with infectious disease specialist involvement and other documented prerequisites.

    Prior Authorization, Documentation & Step Therapy Requirements

    Prior Authorization

    Prior authorization required

    Many specialty outpatient prescription products in this section require prior authorization before benefit consideration; providers must submit indication-specific documentation, prior therapy history (trial and failure/contraindication/intolerance), and prescriber specialty/consultation as specified for the drug and indication.

    Documentation Required

    UC timing and documentation

    Ulcerative colitis initial approvals have a shorter initial coverage duration (12 weeks) and require documentation of disease severity and prior therapy response; reauthorizations require evidence of clinical response and are typically 12 months.

    Prior Authorization

    Benefit determination required

    For some agents the benefit must be determined as Part B versus Part D; prior authorization submissions should note which benefit applies when indicated (drug-specific entries note Part B vs. Part D review).

    Prior Authorization

    Benlysta prior authorization

    Benlysta prior authorization requires documentation of active SLE or active lupus nephritis, autoantibody positivity, current standard‑of‑care treatment, and prescriber specialty; Benlysta initial and reauthorization approvals are for 6 months.

    • Document active SLE or active lupus nephritis and ANA ≥1:80 or anti-dsDNA ≥30 IU/mL
    • Prescribed by or in consultation with rheumatologist (SLE) or nephrologist/rheumatologist (lupus nephritis)
    • Initial/reauth coverage: 6 months
    Prior Authorization

    Chenodal (Gaucher) PA requirements

    Chenodal prior authorization requires documentation of the radiolucent gallstone diagnosis, oral cholecystography showing a well‑opacifying gallbladder, and documentation of trial and failure (or contraindication/intolerance) to ursodiol; the policy lists a 12‑month coverage duration.

    • Provide oral cholecystography demonstrating a well‑opacifying gallbladder
    • Document trial and failure, contraindication, or intolerance to ursodiol
    • Coverage duration: 12 months
    Prior Authorization

    Cinryze PA requirements

    Cinryze prior authorization for prophylaxis requires diagnostic confirmation of hereditary angioedema by the specified laboratory pathways and specialty prescriber; initial approval is for patients ≥6 years and coverage is 12 months.

    • Document HAE diagnosis via low C4 plus C1‑INH antigenic or functional deficiency OR normal C4/C1‑INH with pathogenic mutation or family history
    • Prescribed by or in consultation with an immunologist/allergist
    • Initial age ≥6 years; coverage duration: 12 months
    Prior Authorization

    Cosentyx PA requirements

    Cosentyx prior authorization requires meeting indication‑specific criteria (e.g., plaque psoriasis BSA or PsA/AS activity), documentation of required prior therapy trials or step therapy, and appropriate specialist prescribing; initial approvals are typically 6 months with 12‑month reauthorization.

    • Document moderate‑to‑severe plaque psoriasis (≥3% BSA or special‑site involvement) or active PsA/AS per indication
    • Provide trial and failure/TF/C/I to required topical or systemic therapies or two listed agents for certain PsA/AS presentations
    • Prescribed by or in consultation with dermatologist or rheumatologist as specified
    • Initial coverage: 6 months; reauth: 12 months
    Prior Authorization

    Pyrimethamine prior authorization

    Pyrimethamine prior authorization is required for toxoplasmosis indications; submit documentation that therapy is for active treatment, secondary prophylaxis, congenital toxoplasmosis, or primary prophylaxis when TMP‑SMX intolerance/desensitization failure is documented; requests for malaria use are excluded.

    • Document toxoplasmosis indication (active, secondary prophylaxis, or congenital)
    • For primary prophylaxis, document TMP‑SMX intolerance and failed desensitization or life‑threatening prior reaction
    • Coverage duration: 12 months; malaria treatment/prophylaxis with pyrimethamine is not authorized
    Prior Authorization

    Enbrel prior authorization

    Enbrel prior authorization requires documentation of the indicated diagnosis and evidence of prerequisite conventional therapy trial and failure (e.g., minimum 3‑month TF/C/I to a conventional DMARD for RA); initial coverage durations are indication‑specific.

    • For RA: document moderately to severely active RA and a 3‑month TF/C/I to methotrexate, leflunomide, or sulfasalazine
    • Prescribed by or in consultation with a rheumatologist for rheumatology indications
    • Initial coverage typically 6 months; reauth 12 months
    Prior Authorization

    Dupixent prior authorization

    Dupixent prior authorization requires indication‑specific documentation (e.g., baseline eosinophil counts for eosinophilic asthma, prior controller therapy trials, histology and PPI/topical steroid trial for EoE) and prescriber specialty as specified.

    • Eosinophilic asthma: baseline eosinophils ≥150 cells/mcL and prior exacerbation history as specified
    • EoE: ≥15 eosinophils/HPF, exclusion of other causes, weight ≥15 kg, and failed 8‑week PPI or topical esophageal steroid
    • Prescribed by or in consultation with appropriate specialist (pulmonologist, gastroenterologist, dermatologist/allergist)
    Prior Authorization

    General prior authorization

    Many drugs require general prior authorization submissions that include diagnosis, prescriber specialty (when specified), evidence of prior therapy trials or response, and the specific required clinical information per product.

    Prior Authorization

    Evrysdi prior auth

    Evrysdi prior authorization requires genetic confirmation of 5q SMN1 mutation/deletion and SMN2 copy number, baseline standardized motor function testing, and documentation that the patient is not receiving concomitant chronic SMN‑modifying therapy.

    • Include genetic test confirming 5q SMN1 mutation/deletion and SMN2 copy number
    • Provide baseline motor exam (HINE‑2, HFMSE, RULM, CHOP‑INTEND, MFM‑32, or Bayley Item 22)
    • Do not use concomitantly with chronic SMN‑modifying therapy (e.g., Spinraza)
    Prior Authorization

    HAE (initial) prior authorization

    Initial HAE acute‑attack treatments require prior authorization with laboratory diagnostic evidence (C4 and C1‑INH antigenic or functional levels) or documented pathogenic mutation/family history for HAE‑nl‑C1INH, and appropriate specialist prescribing.

    • Document low C4 plus C1‑INH antigenic or functional deficiency OR normal C4/C1‑INH with pathogenic mutation or family history
    • Prescribed by or in consultation with an immunologist or allergist
    • Initial age requirement for some agents: 18 years or older (as specified)
    Prior Authorization

    Biologics prior authorization

    Biologic agents require prior authorization documenting the indication, prerequisite therapy trials (TF/C/I) where applicable, specialist prescriber or consultation, and indication‑specific clinical measures; reauthorization requires evidence of clinical response.

    • Document diagnosis consistent with the indication (RA, PsO, PsA, AS, CD, UC, etc.)
    • Provide TF/C/I evidence for required conventional/topical therapies (durations vary by indication)
    • Prescriber specialty and reauth response metrics as specified
    Prior Authorization

    Prior authorization required for Inflectra and similar agents

    Inflectra and similar infliximab‑class agents require prior authorization with indication‑specific documentation (diagnosis, disease severity measures like CDAI or stool frequency), and evidence of TF/C/I to specified conventional therapies; initial approval durations differ from reauthorization (commonly 6 months initial, 12 months reauth).

    • For Crohn's: document CDAI >220 or relevant clinical features and TF/C/I to immunomodulators or corticosteroids
    • For UC: document disease severity (e.g., >6 stools/day, ulcers) and TF/C/I to corticosteroids and aminosalicylates/azathioprine/6‑MP
    • Prescriber restrictions and durations: initial 6 months, reauth 12 months
    Prior Authorization

    Product-level prior authorization required

    Product‑level prior authorization entries for targeted or genetically guided therapies require documentation of diagnosis, specific mutation or biomarker test results, prior therapy history when required, and information about planned combinations; coverage durations are typically noted (commonly 12 months).

    • Submit FDA‑approved or CLIA‑certified test results for required mutations/biomarkers (e.g., PIK3CA, RET, ROS1, NTRK, FLT3, KRAS G12C)
    • Document prior therapy exposure or combinations as specified
    • Coverage durations commonly 12 months
    Prior Authorization

    Product-specific prior authorization

    Providers must submit product‑specific prior authorization information: diagnosis, required biomarker or mutation results (when applicable), prior therapy history, and prescriber specialty/consultation as indicated by the product entry.

    • Include required biomarker/mutation confirmation (FDA‑approved or CLIA test) where listed
    • Provide prior systemic therapy history when prerequisite Part D drugs are required
    • Indicate specialist prescriber or consultation per product
    Prior Authorization

    Prior authorization and coverage duration

    Prior authorization submissions must include all required medical information specified for the product (diagnosis, labs, imaging, mutation tests, prior therapy); many products have set initial and reauthorization coverage durations (often initial 6 or 12 months and reauth 12 months).

    • Provide required diagnostic, laboratory, imaging, and prior therapy documentation
    • Expect coverage durations commonly set to 6 months initial (some) and 12 months reauthorization
    Prior Authorization

    Prior authorization required per drug-specific criteria

    Prior authorization determinations are made against drug‑ and indication‑specific clinical criteria (diagnosis duration, lab thresholds, prior TF/C/I); ensure submitted evidence directly meets the listed criteria.

    Prior Authorization

    Prior authorization requirement

    Certain agents require prior authorization with documentation of diagnosis, prescriber specialty where specified, and evidence of benefit or TF/C/I as detailed in each drug's criteria.

    Prior Authorization

    Prior authorization required

    Prior authorization requests must include diagnosis, pertinent labs, and prescriber specialty when specified; initial authorization durations vary by indication (commonly 6 or 12 months).

    Prior Authorization

    Product-specific prior authorization

    Product‑specific prior authorization is required across multiple entries; providers must document diagnosis, required test results, and prior therapy as listed for the product to support approval.

    Step Therapy

    Conventional DMARD trial required

    For biologic therapy initiation in RA and related conditions, a trial and failure (or contraindication/intolerance) to conventional DMARDs (e.g., methotrexate, leflunomide, sulfasalazine) of specified minimum duration is required before approval.

    • RA: minimum 3‑month trial and failure/TF/C/I to one conventional DMARD at maximally tolerated dose
    • PJIA: minimum 6‑week trial and failure/TF/C/I to methotrexate or leflunomide
    Step Therapy

    Caplyta step requirements

    Caplyta step requirements (for psychiatric indications) mandate documented trial and failure, contraindication, or intolerance to specified generic antipsychotics prior to approval as outlined in the product entry.

    Step Therapy

    Cosentyx step therapy

    Cosentyx INJ 125 mg step therapy for certain PsA and AS presentations requires trial and failure/intolerance to two listed alternative agents (or continuation of prior therapy) before Cosentyx initial approval.

    • TF/C/I to two agents among Cosentyx SC, Enbrel, a formulary adalimumab, Orencia, Otezla, Skyrizi, a formulary ustekinumab, Rinvoq, or Xeljanz/XR, or continuation of prior therapy
    Step Therapy

    Onychomycosis step therapy

    Topical ciclopirox nail lacquer requires documentation confirming onychomycosis (KOH, culture, or histology) and a documented trial and failure, contraindication, or intolerance to oral terbinafine (minimum 6 weeks for fingernails; 12 weeks for toenails) before approval.

    • Provide positive KOH, culture, or histology confirming onychomycosis
    • Document TF/C/I to oral terbinafine (6 weeks fingernail; 12 weeks toenail)
    Step Therapy

    Dulera step therapy

    Dulera requires prior trial and failure, contraindication, or intolerance to Breo Ellipta (fluticasone furoate + vilanterol) before initiation, per the product's step therapy requirements.

    Step Therapy

    Empaveli step requirement

    Empaveli for C3G/primary IC‑MPGN requires documentation that the patient has been treated with a maximally tolerated ACE inhibitor or ARB or an SGLT2 inhibitor for at least 12 weeks prior to initiation; provide nephrology prescribing/consultation.

    • Document ≥12 weeks of maximally tolerated ACEI/ARB or SGLT2 inhibitor therapy prior to Empaveli initiation
    • Prescribed by or in consultation with a nephrologist
    Step Therapy

    Enbrel step therapy

    Enbrel step therapy requires prior trials of conventional DMARDs (methotrexate, leflunomide, sulfasalazine) for RA and similar conventional therapy trials for PJIA before biologic initiation.

    • Document TF/C/I to conventional DMARDs per indication (e.g., 3 months for RA)
    Step Therapy

    Prerequisite therapy where required

    Some indications specify prerequisite Part D drug use (documented prior therapy) before approval — for example, many rheumatology biologics and certain asthma indications require prior Part D drug therapy as noted in product entries.

    Step Therapy

    Step therapy for biologics

    Step therapy for biologics generally requires documented trial and failure, contraindication, or intolerance to specified conventional or topical therapies for minimum durations (e.g., topical trials for psoriasis, DMARDs for RA) prior to biologic approval.

    • Topical therapy trial durations (e.g., 30 days topical; 14 days for topical corticosteroids) for psoriasis prior to biologic
    • Conventional DMARD durations (e.g., 3 months for RA)
    Step Therapy

    Step therapy / TF/C/I

    Many biologic and advanced therapies require documented trial and failure, contraindication, or intolerance (TF/C/I) to specified conventional agents before approval; providers must supply evidence of those prior attempts.

    Step Therapy

    Antifungal step therapy

    Itraconazole and other antifungal approvals require documented trial and failure (or contraindication/intolerance) to oral terbinafine for onychomycosis (fingernail: minimum 6‑week supply; toenail: minimum 12‑week supply) before approval.

    • Document TF/C/I to oral terbinafine (6 weeks fingernail; 12 weeks toenail)
    • Provide confirmatory KOH, culture, or biopsy as applicable
    Step Therapy

    Step therapy / prior treatment requirements

    Several oncology and supportive‑care products require prior trials or failures of specified prior systemic therapies (e.g., Lonsurf requires prior fluoropyrimidine-, oxaliplatin-, and irinotecan‑based chemotherapy and anti‑VEGF therapy for metastatic colorectal cancer).

    • Document prior exposure to required chemotherapy regimens and anti‑VEGF therapy where listed
    Step Therapy

    Step therapy / prior drug trials

    Many products require trial and failure or intolerance to specified agents prior to approval (examples include requirement to trial a triptan before certain acute migraine agents or prior corticosteroid trials for eosinophilic conditions); support with documentation.

    Step Therapy

    Orencia step therapy

    Orencia step therapy requires documented TF/C/I to specified conventional DMARDs for RA and PJIA (e.g., 3 months for RA; 6 weeks for PJIA) prior to approval; prescriber restriction to rheumatology applies.

    • RA: document 3‑month TF/C/I to methotrexate, leflunomide, or sulfasalazine
    • PJIA: document 6‑week TF/C/I to methotrexate or leflunomide
    • Prescribed by or in consultation with a rheumatologist
    Step Therapy

    Step therapy for topical diclofenac

    Topical diclofenac for knee osteoarthritis requires trial and failure, contraindication, or intolerance to at least two prescription‑strength topical or oral NSAIDs (or specified risk conditions) before approval.

    • Document TF/C/I to ≥2 prescription‑strength topical or oral NSAIDs or presence of qualifying GI risk factors
    Step Therapy

    Step therapy / prerequisite therapy

    Many immunomodulatory and biologic agents (e.g., Rinvoq, Rinvoq Lq) require prior trials and failure, contraindication, or intolerance to specified conventional therapies and/or TNF inhibitors before approval; providers must document prior therapy attempts.

    Step Therapy

    Topical therapy trial required for psoriasis indications

    For plaque psoriasis and PsA biologics (e.g., Skyrizi, Stelara), a trial and failure of specified topical therapies is required before approval for many initial indications; document topical therapy trials per product notes.

    • Provide evidence of topical therapy TF/C/I (minimum 30‑day supply or 14 days for topical corticosteroids) prior to biologic initiation
    Documentation Required

    AAT deficiency diagnostic data

    For alpha‑1 antitrypsin augmentation, document genotype (e.g., PiZZ) and pre‑treatment serum AAT level <11 µM/L (or corresponding mg/dL equivalents) and diagnosis of emphysema to support authorization.

    • Include genotype (eg, PiZZ) and pre‑treatment serum AAT <11 µM/L
    • Document diagnosis of emphysema
    Documentation Required

    Migraine baseline and response

    For CGRP preventive therapy for migraine, document baseline migraine days per month and decreased use of acute migraine medications on therapy for reauthorization (initial coverage 6 months; reauth 12 months).

    • Document baseline migraine days/month (episodic ≥4; chronic ≥8)
    • For reauth, show decreased acute medication use and clinical response
    Documentation Required

    Benlysta required clinical info

    Benlysta prior authorization requires documentation of active SLE or lupus nephritis, autoantibody positivity (ANA ≥1:80 or anti‑dsDNA ≥30 IU/mL), current standard‑of‑care therapy, prescriber specialty, and age eligibility for IV/SC formulations (≥5 years); initial/reauth coverage is 6 months.

    • Document active SLE or active lupus nephritis and autoantibody positivity
    • Prescribed by or in consultation with a rheumatologist (SLE) or nephrologist/rheumatologist (lupus nephritis)
    • Age ≥5 years for IV/SC formulations; coverage 6 months
    Documentation Required

    Tumor molecular testing

    Tumor‑targeted therapies require submission of tumor type, the specified molecular alteration (e.g., ROS1, NTRK, RET, BRAF, KRAS G12C) detected by an FDA‑approved or CLIA‑certified test, and prior systemic therapy history or that no satisfactory alternatives exist.

    • Attach FDA‑approved or CLIA‑certified test results confirming the genomic alteration
    • Document disease extent (locally advanced/metastatic) and prior therapy exposure or lack of alternatives
    Documentation Required

    Bronchitol tolerance test

    Bronchitol prior authorization requires documented CF diagnosis and evidence of passing the Bronchitol Tolerance Test (BTT); initial coverage is 6 months and reauth 12 months with evidence of benefit.

    • Provide documentation of CF diagnosis
    • Include Bronchitol Tolerance Test (BTT) results showing passage
    Documentation Required

    Gaucher disease testing

    Gaucher disease entries require documentation of Gaucher disease type 1 and CYP2D6 metabolizer status determined by an FDA‑cleared test for product selection; some products list age and coverage duration requirements (e.g., 12 months).

    • Provide diagnosis of Gaucher disease type 1
    • Submit CYP2D6 metabolizer status from an FDA‑cleared test
    Documentation Required

    Chenodal required imaging and therapy history

    For Chenodal approval, provide oral cholecystography demonstrating a well‑opacifying gallbladder, documentation that ursodiol was tried and failed (or is contraindicated/intolerant), and confirmation that stones are radiolucent and patient is not a surgical candidate.

    • Oral cholecystogram showing well‑opacifying gallbladder
    • Document TF/C/I to ursodiol or surgical ineligibility
    • Confirm stones are radiolucent (not calcified/radiopaque pigment stones)
    Documentation Required

    Onychomycosis confirmation

    Onychomycosis topical lacquer requires confirmation of onychomycosis by KOH, culture, or histology and documentation of trial and failure, contraindication, or intolerance to oral terbinafine (6 weeks for fingernails; 12 weeks for toenails) before coverage.

    • Include positive KOH, culture, or histology confirming onychomycosis
    • Document TF/C/I to oral terbinafine with duration per nail type
    Documentation Required

    Cinryze lab/genetic documentation

    Cinryze prophylaxis authorization must include C4 level and C1‑INH antigenic or functional level results; for HAE‑nl‑C1INH, include genetic testing demonstrating a pathogenic mutation or a confirmed family history.

    • Submit C4 and C1‑INH antigenic or functional lab results
    • For HAE‑nl‑C1INH, include genetic testing or confirmed family history
    Documentation Required

    Deferasirox required baseline labs and transfusion history

    Deferasirox initial authorization for transfusional iron overload requires baseline ferritin >1,000 mcg/L and documentation of transfusion history of at least 100 mL/kg of packed RBCs; reauthorization requires reduction from baseline in ferritin or liver iron concentration.

    • Baseline ferritin >1,000 mcg/L
    • Document transfusion history (≥100 mL/kg packed RBCs)
    • Reauth: demonstrate reduction from baseline in ferritin or LIC
    Documentation Required

    Dupixent EoE diagnostic documentation

    Dupixent for EoE requires histologic confirmation (≥15 intraepithelial eosinophils per high power field), exclusion of other causes, weight ≥15 kg, and documentation of TF/C/I to an 8‑week PPI or topical esophageal corticosteroid prior to approval.

    • Provide biopsy showing ≥15 eos/HPF and exclude other causes
    • Document weight ≥15 kg
    • Document TF/C/I to an 8‑week PPI or topical esophageal steroid
    Documentation Required

    Empaveli prerequisite therapy documentation

    Empaveli prior authorization requires documentation that patients with C3G or primary IC‑MPGN have been treated with a maximally tolerated ACEI/ARB or SGLT2 inhibitor for at least 12 weeks prior to initiation; for primary IC‑MPGN the patient must not have had a kidney transplant.

    • Document ≥12 weeks of maximally tolerated ACEI/ARB or SGLT2 inhibitor
    • Primary IC‑MPGN: confirm patient has not had kidney transplant
    Documentation Required

    Rheumatology/psoriasis documentation

    Rheumatology and dermatology biologics require documentation of diagnosis, specialist prescriber or consultation (rheumatologist/dermatologist), and evidence of prior therapy response or TF/C/I as applicable; reauthorization requires demonstration of clinical response.

    • Document diagnosis and prescriber specialty (rheumatologist/dermatologist)
    • Provide TF/C/I evidence for prerequisite therapies where required
    • Reauth: supply indication‑specific response metrics (joint counts, BSA, etc.)
    Documentation Required

    SMA documentation

    Evrysdi documentation must include genetic testing confirming 5q SMN1 mutation/deletion, SMN2 copy number, baseline motor function test scores (HINE‑2, CHOP‑INTEND, HFMSE, RULM, MFM‑32, or Bayley Item 22), and records regarding prior gene therapy and response if applicable.

    • Submit genetic confirmation of 5q SMN1 mutation/deletion and SMN2 copy number
    • Provide baseline motor exam scores with an appropriate standardized tool
    • If prior gene therapy given, include documentation of inadequate response
    Documentation Required

    HAE diagnostic documentation

    HAE diagnostic documentation for authorization must include a C4 level and C1‑INH antigenic or functional levels, or for HAE‑nl‑C1INH include genetic testing demonstrating a pathogenic mutation or a confirmed family history of recurrent angioedema.

    • Provide C4 and C1‑INH antigenic or functional lab values
    • For HAE‑nl‑C1INH include pathogenic gene mutation testing or confirmed family history
    Documentation Required

    HAE diagnostic evidence

    For HAE initial therapy, document either (1) low C4 plus C1‑INH antigenic or functional deficiency OR (2) normal C4/C1‑INH with a documented pathogenic mutation or confirmed family history; lack of these will trigger denial.

    Documentation Required

    Biologic therapy documentation

    Biologic therapy documentation must include indication‑specific diagnostic evidence and prior therapy trials as applicable; reauthorization requires documented positive clinical response (e.g., reduced swollen/tender joint count, BSA reduction for psoriasis).

    • Submit indication‑specific diagnostic criteria and TF/C/I evidence
    • Reauth: provide clinical response metrics relevant to indication
    Documentation Required

    Growth hormone diagnostic documentation

    Growth hormone product requests must include the specific growth disorder diagnostic criteria, bone age limits for initial therapy, and stimulation test results or growth metrics per indication; prescriber is typically an endocrinologist.

    • Provide diagnostic criteria (PGHD, PWS, GFSGA, SHOX deficiency, AGHD, etc.)
    • Include bone age limits (male <16 years; female <14 years) where applicable
    • Attach GH stimulation test results when required
    Documentation Required

    IBD documentation

    IBD initial requests (Crohn's disease, ulcerative colitis) must include diagnosis, objective disease activity measures (e.g., CDAI >220, stool frequency, ulcers, abnormal labs), and documentation of TF/C/I to specified conventional therapies.

    • For Crohn's: include CDAI >220 or clinical features and TF/C/I to immunomodulators/corticosteroids
    • For UC: document stool frequency, presence of ulcers, labs, and TF/C/I to corticosteroids and aminosalicylates/azathioprine/6‑MP
    Documentation Required

    Reauthorization response documentation

    Reauthorization requests across inflammatory and biologic indications must document positive clinical response using indication‑specific metrics (e.g., joint counts for RA/PsA, BSA for psoriasis, improvement in inflammatory markers or mucosal healing for IBD).

    • Provide objective measures of improvement versus baseline (e.g., reduced swollen/tender joint count, decreased BSA, mucosal healing, improved labs)
    Documentation Required

    Immune globulin documentation

    Immune globulin (IVIG/SCIG) authorizations must include diagnosis, evidence of minimum effective dosing and frequency, and immunologic evaluation (including IgG levels and vaccine response) when applicable; reauthorization requires objective improvement.

    • Provide diagnosis meeting listed primary or secondary immunodeficiency or other approved condition
    • Include IgG levels and vaccine response data where applicable
    • Document minimum effective IVIG dosing/frequency and objective improvement for reauth
    Documentation Required

    Liver monitoring for tolvaptan

    Tolvaptan (Jynarque) prior authorization requires documentation of rapidly progressing ADPKD and adherence to the liver function monitoring schedule (baseline and periodic ALT/AST/bilirubin checks); reauthorization requires demonstration of benefit or absence of hepatic injury.

    • Document rapidly progressing ADPKD
    • Provide baseline and scheduled LFTs per monitoring schedule (2 and 4 weeks after initiation, then monthly for first 18 months or every 3 months after 18 months)
    Documentation Required

    Essential clinical documentation

    Providers must include essential clinical documentation for targeted and specialty agents: diagnosis, mutation/test results (e.g., KRAS G12C, EGFR, BRAF V600E/K), prior systemic therapy history when required, and specialty prescriber/consultation when requested.

    Documentation Required

    Genetic testing documentation

    For Livmarli in ALGS or PFIC, molecular genetic testing confirming the specified gene mutations (JAG1, NOTCH2, ATP8B1, ABCB11, ABCB4, TJP2, NR1H4, or MYO5B) must be provided to support authorization.

    • Attach molecular genetic testing confirming the listed gene mutation(s)
    Documentation Required

    BRAF mutation test

    When BRAF mutation‑directed therapies are requested, submit tumor testing demonstrating BRAF V600E or V600K mutation by an FDA‑approved or CLIA‑certified test as specified in the product entry.

    Documentation Required

    Diagnosis and supporting records

    Medical records confirming diagnosis and supporting data (e.g., T2DM labs for Mounjaro, chemotherapy regimen and febrile neutropenia risk for Neulasta) must be provided as specified by product criteria.

    Documentation Required

    ILD diagnostic documentation

    ILD diagnostic documentation for IPF and SSc‑ILD requires exclusion of other known causes and HRCT and/or surgical lung biopsy findings consistent with IPF or SSc‑ILD per the product criteria.

    • Provide HRCT showing UIP/probable IPF pattern or surgical lung biopsy supporting IPF/SSc‑ILD
    • Document exclusion of other known causes of ILD
    Documentation Required

    hATTR diagnostic documentation

    hATTR amyloidosis documentation must include a pathogenic TTR mutation detected by FDA‑approved or CLIA‑certified testing and baseline neurologic scores (PND ≤ IIIb, FAP stage 1–2, or NIS between 5 and 130) to support initiation.

    • Submit confirmed pathogenic TTR mutation test result
    • Provide baseline PND, FAP stage, or NIS per criteria
    Documentation Required

    Required diagnostic documentation

    Required diagnostic documentation for certain metabolic and systemic indications (e.g., T2DM, MASH) must include chart notes or lab evidence (A1c ≥6.5% or equivalent for T2DM; FAST/MAST or liver biopsy and FibroScan/FIB‑4 confirming F2‑F3 for MASH).

    • For T2DM: provide chart notes or labs showing A1c ≥6.5% or FPG ≥126 mg/dL or 2‑hr OGTT ≥200 mg/dL
    • For MASH: submit FAST/MAST or liver biopsy and fibrosis stage F2 or F3 via FibroScan/FIB‑4/equivalent
    Documentation Required

    Genetic test documentation

    For cystic fibrosis modulators (e.g., Orkambi), prior authorization requires documentation of homozygous F508del CFTR mutation confirmed by an FDA‑cleared or CLIA‑approved test and prescribing by a CF care center specialist or pulmonologist.

    • Provide CFTR mutation testing confirming homozygous F508del
    • Prescribed by or in consultation with CF care center specialist/pulmonologist
    Documentation Required

    Genomic testing and disease documentation

    Targeted therapy prior authorization requires submission of documentation of diagnosis, disease extent (advanced/metastatic), and presence of the required genomic alteration detected by an FDA‑approved or CLIA‑certified test.

    Documentation Required

    Diagnostic and mutation status

    For hematologic malignancy agents (e.g., Rydapt), include diagnostic confirmation and mutation status testing when specified; for Rydapt in newly diagnosed FLT3‑mutated AML, document FLT3 mutation by an FDA‑approved/CLIA test and concomitant use with standard induction/consolidation regimens.

    • Submit FLT3 mutation test result (FDA‑approved or CLIA)
    • Document planned or concurrent use with cytarabine/daunorubicin induction and cytarabine consolidation for AML
    Documentation Required

    Rydapt — diagnostic and regimen documentation

    Rydapt authorization specifically requires documentation of FLT3 mutation positivity detected by an FDA‑approved or CLIA‑certified test and concurrent use with standard cytarabine and daunorubicin induction and cytarabine consolidation for newly diagnosed AML.

    Documentation Required

    Hizentra — required clinical documentation

    Hizentra (SCIG) authorizations must include the diagnosis (CIDP or listed primary immunodeficiencies), baseline IgG levels and inadequate vaccine response when applicable, dosing at the minimum effective dose, and specialist prescribing or consultation.

    • Provide diagnosis and baseline IgG
    • Document inadequate vaccine response when applicable
    • Prescribed by or in consultation with an appropriate specialist
    Documentation Required

    Skyrizi — baseline and reauth documentation

    Skyrizi and similar biologic prior authorization requires documentation of indication (psoriasis, PsA, CD, UC), baseline disease severity measures (BSA, CDAI, stool frequency, CRP), prior topical/systemic therapy trials when required, and response data for reauthorization.

    • Include baseline BSA for psoriasis or CDAI for Crohn's disease
    • Provide TF/C/I evidence for prior topical or systemic therapies as applicable
    • Reauth: submit evidence of clinical response
    Denial Risk

    Documentation of prior therapy

    Failure to document TF/C/I to required conventional therapies (e.g., methotrexate, leflunomide, sulfasalazine for RA) will risk denial; include dates, doses, and reasons for discontinuation.

    • Document trial durations, doses, and objective evidence of failure or intolerance
    • Include contraindication rationale if applicable
    Denial Risk

    PAH diagnostic confirmation

    For PAH agents, absence of right heart catheterization confirmation of diagnosis or lack of documentation that the patient is currently on PAH therapy may trigger denial; include hemodynamic confirmation or current PAH treatment evidence.

    • Provide right heart catheterization results confirming PAH when available
    • Or document that the patient is currently receiving PAH therapy
    Denial Risk

    Documentation-based denials

    Lack of documented diagnosis or failure to meet specific drug indication requirements (for example, MAC lung disease criteria for Arikayce) may result in denial; ensure required clinical evidence and specialist consultation are included.

    Denial Risk

    Ursodiol trial required for Chenodal

    Failure to document trial and failure, contraindication, or intolerance to ursodiol for radiolucent gallstones will trigger denial for Chenodal requests; include imaging and ursodiol trial details.

    Denial Risk

    Diagnostic confirmation and terbinafine trial for Ciclopirox Nail Lacquer

    Requests for topical ciclopirox lacquer will be denied if confirmation of onychomycosis (KOH, culture, or histology) or documentation of TF/C/I to oral terbinafine is absent; provide diagnostic test results and terbinafine trial history.

    Denial Risk

    HAE diagnostic testing for Cinryze

    Cinryze prophylaxis may be denied if laboratory confirmation of HAE (C4 and C1‑INH antigenic or functional levels) is absent or if required genetic testing/family history for HAE‑nl‑C1INH is not provided.

    Denial Risk

    Pyrimethamine: malaria excluded

    Requests for any pyrimethamine product submitted for malaria treatment or prophylaxis are not authorized and will be denied; pyrimethamine is only authorized per the toxoplasmosis criteria.

    Denial Risk

    Diacomit combination/weight requirement

    Diacomit must be used in combination with clobazam and the patient must weigh ≥7 kg for approval; lack of combination therapy documentation or weight threshold will risk denial.

    • Document concomitant clobazam use
    • Provide patient weight (≥7 kg)
    Denial Risk

    Enbrel prerequisite therapy

    Enbrel initial RA requests will be denied if there is no documentation of a 3‑month trial and failure/contraindication/intolerance to a conventional DMARD (methotrexate, leflunomide, sulfasalazine); include therapy dates and outcomes.

    Denial Risk

    Rheumatology reauth denial triggers

    Reauthorization for rheumatology/immunology biologics may be denied if providers fail to demonstrate positive clinical response at reauth (e.g., reduced swollen/tender joint count, symptom improvement) or fail to meet prescriber restrictions.

    Denial Risk

    Evrysdi documentation denial triggers

    Evrysdi requests lacking baseline genetic confirmation (5q SMN1 mutation/deletion and SMN2 copy number) or absence of required baseline motor exam results may be denied; supply genetic and baseline motor testing documentation.

    Denial Risk

    HAE diagnostic documentation

    Acute HAE attack treatment requests will be denied if the diagnosis of HAE is not documented by required laboratory evidence (low C4 plus C1‑INH antigenic or functional deficiency, or normal C4/C1‑INH with documented pathogenic mutation or family history).

    Denial Risk

    RA prerequisite therapy

    For RA biologic initiation, failure, contraindication, or intolerance to a 3‑month trial of a conventional DMARD (methotrexate, leflunomide, sulfasalazine) is required or the claim may be denied; include trial duration and outcome.

    Denial Risk

    Documentation of prior conventional therapy

    Failure to document required conventional therapy trials (e.g., for Crohn's disease: 6‑mercaptopurine, azathioprine, corticosteroids, methotrexate) may trigger denial for IBD biologics; include trial durations and reasons for discontinuation.

    Denial Risk

    NSAID trial requirement

    For ankylosing spondylitis and related indications, absence of a documented trial and failure or intolerance to an NSAID at maximally tolerated doses (minimum 1 month) may result in denial; include NSAID trial details.

    Denial Risk

    Breast cancer targeted therapy — documentation required

    Breast cancer targeted therapy requests (e.g., PIK3CA‑mutated HR+/HER2‑) will be denied if required diagnostic documentation (PIK3CA mutation) or documentation of prior adjuvant endocrine therapy/co‑therapies is missing.

    Denial Risk

    PAH confirmation required

    PAH agent requests lacking documentation of right heart catheterization confirmation or evidence that the patient is currently on PAH therapy may not meet initial coverage requirements and risk denial.

    Denial Risk

    MS combination therapy exclusion

    Use of multiple disease‑modifying therapies in combination for MS is excluded and may lead to denial; ensure requests indicate monotherapy or appropriate continuation of prior single DMT.

    Denial Risk

    Eosinophil and prior therapy requirements

    Failure to demonstrate required baseline eosinophil counts or prior treatment trials for eosinophil‑targeted agents (e.g., Nucala indications) may trigger denial; include baseline eosinophil values and prior therapy history.

    • Provide baseline eosinophil counts (e.g., ≥150 cells/µL or ≥300 cells/µL in past 12 months as applicable)
    • Document prior corticosteroid or other required therapy trials
    Denial Risk

    HES documentation

    HES authorizations will be denied if the diagnosis has not been present for at least 6 months, secondary causes are not ruled out, FIP1L1‑PDGFRA fusion status is not negative, or pre‑treatment eosinophils <1,000 cells/µL; include documentation per criteria.

    Denial Risk

    Documentation-triggered denial risk

    For MASH therapies, lack of documentation confirming diagnosis and fibrosis stage (F2 or F3) using FAST, MAST, FibroScan, FIB‑4, or liver biopsy may trigger denial; include the specified diagnostic test results.

    Denial Risk

    Hemoglobin/Hematocrit thresholds for denial

    Erythropoiesis‑stimulating agent (Retacrit) requests will be denied for off‑label uses (except MDS, HCV) when patient hemoglobin >10 g/dL or hematocrit >30%; ensure labs meet indication‑specific thresholds and adequate iron stores (ferritin >100 mcg/L and TSAT >20%) are documented.

    • Provide recent Hgb/Hct meeting indication thresholds
    • Document iron stores (ferritin >100 mcg/L and TSAT >20%) when required
    Denial Risk

    Vigabatrin — prerequisite failure documentation

    Vigabatrin for complex partial seizures requires documentation of failure, contraindication, or intolerance to two formulary anticonvulsants prior to approval; lacking this documentation risks denial.

    • Document TF/C/I to two formulary anticonvulsants (names, durations, outcomes)
    Denial Risk

    Octreotide — acromegaly prerequisite

    Octreotide for acromegaly requires documentation of inadequate response to or ineligibility for surgery/radiation and trial/failure of a dopamine agonist at maximally tolerated doses prior to approval; absence of these will risk denial.

    Referenced Products and Coding Notes

    Products listed (partial)mixed
    Actimmune INJ 100MCG/0.5MLProduct name as listed
    Adalimumab-aaty 1-pen KitProduct name as listed
    Adalimumab-aaty 2-pen KitProduct name as listed
    Adalimumab-aaty 2-syringeProduct name as listed
    Adalimumab-aaty Cd/uc/hs StarterProduct name as listed
    Products listed (partial) - single-item representationmixed
    Actimmune INJ 100MCG/0.5MLProduct name as listed
    Products listed (partial) - other entriesmixed
    Adalimumab-aaty 1-pen KitProduct name as listed
    Adalimumab-aaty 2-pen KitProduct name as listed
    Adalimumab-aaty 2-syringeProduct name as listed
    Adalimumab-aaty Cd/uc/hs StarterProduct name as listed
    Adalimumab productsmixed
    Adalimumab-aatyMultiple packaging configurations listed (1-pen, 2-pen, 2-syringe, starters)
    Adalimumab packaging variantsmixed
    Adalimumab-aaty 1-pen Kit1-pen kit listed in product group
    Adalimumab-aaty 2-pen Kit2-pen kit listed in product group
    Adalimumab-aaty 2-syringe2-syringe listed in product group
    Adalimumab-aaty Cd/uc/hs StarterStarter configuration listed
    CGRP inhibitorsmixed
    AimovigCGRP inhibitor for migraine prevention
    CGRP inhibitor example (Aimovig)mixed
    AimovigProduct name as listed
    Oncology/immunosuppression agentsmixed
    Everolimus TBSOEverolimus oral tablets, multiple strengths (product listed)
    Oncology agent examplemixed
    Everolimus TBSOProduct name as listed
    AAT augmentationmixed
    Prolastin-c INJ 1000MG/20MLAlpha-1 antitrypsin augmentation product
    No explicit CPT/HCPCS/ICD codes listed in this segmentmixed
    No codes listed
    Products listed (no billing codes in excerpt)mixed
    No codes listed
    Covered/Referenced Drugs (no coding listed)mixed
    N/APyrimethamine — policy text provides clinical criteria but no explicit billing codes in this segment
    Biologics and specialty drugs (no codes listed)mixed
    Formulary ID: 26216Formulary identifier referenced in section
    N/ABiologics entries provided without explicit CPT/HCPCS/ICD codes in this excerpt
    Products listed without explicit billing codesmixed
    RydaptProduct name as listed (no CPT/HCPCS/ICD codes provided in excerpt)
    GavretoRET-targeted agent listed; product name present in section 95 without explicit billing codes in excerpt
    Products listed (no codes provided)mixed
    No codes listed
    Referenced guidelines / clinical standardsmixed
    AASLD/IDSA guidelineReferenced guidance for HCV treatment selection with Mavyret
    Document identifiersmixed
    Formulary ID: 26216Document/formulary identifier and version
    Covered/Referenced Codesmixed
    none listedNo CPT/HCPCS/ICD-10 codes provided in this section
    Formulary identificationmixed
    Formulary ID: 26216Formulary version identifier
    Formulary identifiersmixed
    Formulary ID: 26216Formulary identifier for this section/version
    Codes referenced (none specified)mixed
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes listed in this excerpt
    Plaque Psoriasis BSA
    Threshold>= 3% body surface area
    Alternate severe site criteriaSevere scalp, palmoplantar, facial, or genital involvement qualifies
    Prior topical therapyTrial and failure (or CI/intolerance) to a minimum 30-day supply of topical therapy (14 days for topical corticosteroids)
    Episodic Migraines frequency
    Episodic migraine threshold>= 4 migraine days per month
    Age18 years or older for EM/CM initial
    Initial coverage duration6 months (reauthorization 12 months with documented response)
    Chronic Migraines frequency
    Chronic migraine threshold>= 8 migraine days per month
    Medication overuse considerationMedication overuse headache must be considered and offending agents discontinued
    Reauthorization evidenceDecreased use of acute migraine medications and positive clinical response required for reauth
    AAT serum level
    AAT serum level threshold< 11 µM/L (or corresponding mg/dL: <80 mg/dL radial immunodiffusion; <57 mg/dL nephelometry)
    Genotype documentationDocument genotype (e.g., PiZZ) or severe homozygous genotypes per policy
    IndicationDiagnosis of congenital AAT deficiency with emphysema required
    CDAI
    CDAI threshold> 220 (Crohn's Disease Activity Index) indicating moderately to severely active disease
    Alternate evidenceFrequent diarrhea, abdominal pain, weight loss, complications, or abnormal labs may substitute
    Use caseRequired for documentation of moderately to severely active Crohn's disease for biologic initiation
    Platelet count
    Platelet count threshold> 50 x 10^9/L for procedure-related thrombocytopenia (per Doptelet indications)
    ITP threshold noteFor ITP initial: baseline platelet <30,000/mcL with TF/C/I to corticosteroids/IVIG/splenectomy
    PrescriberPrescribed by or in consultation with hematologist/oncologist

    Clinical Definitions and Thresholds

    CDAI
    CDAI as CD criterion> 220 (used to define moderately to severely active Crohn's disease for biologic/Inflectra initiation)
    Documentation requirementDiagnosis and objective disease activity (CDAI >220 or equivalent clinical/lab indicators) must be submitted
    Prior therapy requirementTF/C/I to specified conventional therapies (e.g., 6-MP, azathioprine, corticosteroids, methotrexate) required
    AAT
    AAT diagnostic dataDocument genotype (eg, PiZZ) AND pre-treatment serum AAT < 11 µM/L (or equivalent mg/dL)
    IndicationDiagnosis of congenital AAT deficiency with emphysema required
    ContinuationContinued conventional emphysema treatment required alongside augmentation therapy
    ROS1 rearrangement / NTRK gene fusion
    Required molecular testROS1 rearrangement or NTRK gene fusion must be detected by an FDA‑approved or CLIA‑certified test
    Tumor statusDisease must be locally advanced, metastatic, or unresectable and progressed after prior therapy or have no satisfactory alternative
    DocumentationSubmit tumor type, molecular alteration, and prior therapy history per product-specific requirements
    Autoantibody positive for SLE
    Autoantibody positivityANA titer >= 1:80 OR anti‑dsDNA >= 30 IU/mL required for Benlysta initiation
    Concurrent therapyPatient must be receiving at least one standard‑of‑care treatment for active SLE (eg, antimalarials, corticosteroids, or immunosuppressants)
    PrescriberPrescribed by or in consultation with a rheumatologist (SLE) or nephrologist/rheumatologist (lupus nephritis)
    HAE-nl-C1INH
    HAE‑nl‑C1INH diagnostic pathwayNormal C4 and normal C1‑INH levels PLUS either a pathogenic gene mutation detected by FDA/CLIA test OR confirmed family history of recurrent angioedema
    Alternative diagnostic pathwayLow C4 AND C1‑INH antigenic or functional deficiency (Type I/II) also confirms HAE
    Prescriber and agePrescribed by/consult with immunologist/allergist; prophylaxis age >=6 years; acute attack initial age >=18 years as specified
    nr-axSpA
    nr‑axSpA definitionActive non‑radiographic axial spondyloarthritis with objective signs of inflammation (elevated CRP or sacroiliitis on MRI) without definitive radiographic structural damage
    PrescriberPrescribed by or in consultation with a rheumatologist
    Initial therapy requirementMeets indication‑specific criteria for initiation (eg, prior NSAID trial where specified)
    Eosinophilic esophagitis (EoE)
    EoE histology threshold>= 15 intraepithelial eosinophils per high power field
    Symptom and prior therapyEsophageal dysfunction symptoms AND trial/failure of an 8‑week PPI or topical esophageal corticosteroid required
    Weight requirementPatient must weigh at least 15 kg
    Chronic transfusional iron overload
    Transfusional iron overload thresholdBaseline ferritin > 1,000 mcg/L
    Transfusion historyDocumentation of transfusion of at least 100 mL/kg packed red blood cells required
    Reauth requirementReauthorization requires reduction from baseline in ferritin or liver iron concentration
    Baseline motor exam
    Baseline motor examOne of: HINE‑2, HFMSE, RULM, CHOP‑INTEND, MFM‑32, or Bayley Item 22 performed to document baseline motor function
    Genetic confirmationGenetic testing confirming 5q SMN1 mutation/deletion and SMN2 copy number must be submitted
    Concomitant therapy exclusionNot to be used concomitantly with chronic SMN‑modifying therapy (eg, Spinraza)
    HAE diagnostic confirmation
    HAE diagnostic confirmation — Pathway ALow C4 AND C1‑INH deficiency/dysfunction documented by low antigenic OR low functional C1‑INH (Type I/II)
    HAE diagnostic confirmation — Pathway BNormal C4 and C1‑INH with pathogenic mutation detected by FDA/CLIA test OR confirmed family history (HAE‑nl‑C1INH)
    Age and prescriberAcute HAE attack treatment initial: patient >=18 years and prescriber immunologist/allergist
    HAE-nl-C1INH
    HAE‑nl‑C1INH criteriaNormal C4 and C1‑INH levels plus either pathogenic mutation on FDA/CLIA test or confirmed family history of recurrent angioedema
    Genes referencedExamples: factor XII, plasminogen, ANGPT1, KNG1, MFN, HS3ST6 mutations
    Use limitationsNot used in combination with other approved prophylactic HAE treatments
    TF/C/I
    TF/C/I definitionTrial and failure, contraindication, or intolerance to specified prior therapies (documented)
    Role in step therapyUsed to document prerequisite therapy attempts before approval of subsequent biologic or advanced therapies
    ExamplesRA: 3‑month DMARD trial; PJIA: 6‑week methotrexate/leflunomide trial; AS: 1‑month NSAID trial
    CDAI >220
    CDAI >220 meaningCrohn's Disease Activity Index greater than 220 indicates moderately to severely active disease
    Use for eligibilityCDAI >220 cited as objective disease activity for initiation of biologic therapy in CD/Inflectra criteria
    Alternate clinical indicatorsFrequent diarrhea, abdominal pain, >=10% weight loss, complications, or abnormal labs may also establish severity
    IVIG/SCIG indications and monitoring
    IVIG/SCIG monitoring principleImmune globulin must be administered at the minimum effective dose and frequency for the specified diagnosis
    Required documentationProvide diagnosis, immunologic evaluation (eg, IgG levels, vaccine response), and evidence of minimum effective dosing
    ReauthorizationObjective improvement on therapy and dose/frequency optimization required for reauth
    Rapidly progressing ADPKD
    Rapidly progressing ADPKD requirementDocument diagnosis of rapidly progressing ADPKD and adherence to liver function monitoring schedule (ALT/AST/bilirubin) per Jynarque instructions
    LFT scheduleIf <=18 months on therapy: LFTs prior to initiation, at 2 and 4 weeks, then monthly for first 18 months; if >18 months: at least every 3 months
    ExclusionNo history of significant liver impairment (excluding uncomplicated polycystic liver disease)
    Biomarker/mutation confirmation
    Biomarker/mutation confirmationWhen a biomarker or mutation (eg, KRAS G12C, EGFR exon 19/21, NPM1, FGFR2, BRAF V600E/K) is required, detection by an FDA‑approved or CLIA‑certified test must be submitted
    DocumentationSubmit test name, method, and report showing the specific genomic alteration per product instructions
    Effect on coveragePresence of the specified mutation is required for medical necessity of targeted oncology agents
    BRAF V600E or V600K mutant type
    BRAF mutant requirementTumor must be BRAF V600E or V600K mutant type as detected by an FDA‑approved or CLIA‑certified test
    Use with companion agentsOften required to be used in combination with the indicated companion BRAF/MEK agent per label (eg, dabrafenib) depending on indication
    IndicationsMelanoma, NSCLC, anaplastic thyroid cancer, and other listed indications per product-specific criteria
    FIP1L1-PDGFRA-negative
    FIP1L1‑PDGFRA‑negative requirementPatient must be negative for FIP1L1‑PDGFRA fusion to qualify for certain HES indications
    PurposeEnsures eligibility for HES therapies that exclude patients with FIP1L1‑PDGFRA‑positive disease
    DocumentationSubmit molecular test results from FDA‑approved or CLIA‑certified lab
    Type 2 inflammation (COPD)
    COPD Type 2 inflammation definitionDocumented by blood eosinophils >=150 cells/µL at baseline OR >=300 cells/µL within the past 12 months
    Treatment contextRequired when initiating biologic/targeted therapy for COPD with Type 2 inflammation alongside prior triple therapy or LAMA+LABA if ICS contraindicated
    Evidence timeframeEosinophil result may be baseline or within the prior 12 months as specified
    Homozygous F508del
    Homozygous F508del requirementPatient must be homozygous for the F508del CFTR mutation as confirmed by FDA‑cleared or CLIA‑approved test
    Age and prescriberPatient age >=6 years for initial therapy; prescriber is CF care specialist or pulmonologist
    Reauth evidencePatient must demonstrate benefit (eg, improved FEV1 or fewer exacerbations) for reauthorization
    MASH (formerly NASH)
    MASH diagnostic confirmationMASH (formerly NASH) confirmed by FAST, MAST, or liver biopsy with fibrosis stage F2 or F3
    PrescriberPrescribed by or in consultation with gastroenterologist, endocrinologist, or hepatologist
    Reauth requirementReauthorization requires demonstration of positive clinical response
    Adequate iron stores
    Adequate iron storesFerritin > 100 mcg/L AND transferrin saturation (TSAT) > 20% required prior to ESA (Retacrit) initiation
    ContextApplies to CKD, HIV, chemo, preop, MDS indications where adequate iron stores are prerequisites
    DocumentationSubmit recent ferritin and TSAT results with authorization request
    Genomic alteration
    Genomic alteration requirementPresence of the specified gene fusion or mutation (eg, RET fusion, ROS1 rearrangement, NTRK fusion) detected by an FDA‑approved or CLIA‑certified test
    Disease statusDisease must be advanced/metastatic or unresectable and progressed following prior systemic therapy or have no satisfactory alternatives
    DocumentationSubmit test report and tumor type with the prior therapy history
    FLT3 mutation-positive AML
    FLT3 mutation requirementFLT3 mutation detected by an FDA‑approved or CLIA‑certified test required for Rydapt use in newly diagnosed AML
    Regimen contextUsed in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation per product labeling
    Coverage durationAuthorization typically for 12 months; continuation of prior therapy approved when criteria met
    Primary immunodeficiency (for Hizentra)
    Primary immunodeficiency indicationPrimary immunodeficiencies (eg, CVID, congenital agammaglobulinemia, SCID, Wiskott‑Aldrich) with low IgG and inadequate vaccine response qualify for Hizentra SCIG
    DocumentationProvide diagnosis, baseline IgG levels, evidence of inadequate vaccine response when applicable, and dosing at minimum effective dose
    PrescriberPrescribed by or in consultation with a specialist experienced in SCIG therapy (eg, immunologist)

    Policy Excerpt Context and Scope

    This excerpt covers specialty outpatient agents across multiple clinical areas including immunology, rheumatology, dermatology, gastroenterology, pulmonary, and oncology. For listed products the policy emphasizes requirement of indication‑specific documentation (diagnosis, objective disease measures or biomarker/mutation test results when required), prior therapy trials or rationale for bypassing them, prescriber specialty or consultation where specified, and defined coverage durations.